Role of the MLL-AF4 chimeric protein in the molecular pathogenesis of t(4;11) acute lymphoblastic leukemia by Imperato, Maria Rosaria
European	  School	  of	  Molecular	  Medicine	  	  
Naples	  Site	  
Università	  degli	  Studi	  di	  Napoli	  “Federico	  II”	  




Role	  of	  the	  MLL-­‐AF4	  chimeric	  protein	  in	  the	  molecular	  pathogenesis	  
of	  t(4;11)	  acute	  lymphoblastic	  leukemia	  
	  
PhD	  candidate:	  Maria	  Rosaria	  Imperato	  
Tutor:	  Prof.	  Francesco	  Salvatore	  
Internal	  Supervisor:	  Prof.	  Margherita	  Ruoppolo	  
External	  Supervisor:	  Prof.	  Margaret	  Ann	  Goodell	  
Coordinator:	  Prof.	  Francesco	  Salvatore	  
Academic	  Year:	  2010-­2011	  
	   2	  
Abstract	  
	   	   Chromosomal	  rearrangements	  involving	  the	  Mixed	  Lineage	  Leukemia	  (MLL)	  gene	  are	  
associated	  with	  very	  aggressive	  forms	  of	  acute	  lymphoblastic	  leukemia	  (ALL),	  often	  refractory	  
to	   conventional	   therapies.	   In	   particular,	   patients	   carrying	   the	   translocation	   t(4;11)(q21;q23)	  
have	  the	  worst	  prognosis	  among	  patients	  with	  other	  MLL-­‐associated	  malignancies.	  Although	  it	  
has	   been	   largely	   shown	   that	   the	  MLL-­‐AF4	   fusion	   protein	   has	   the	   capability	   to	   up-­‐regulate	  
genes	  involved	  in	  the	  self-­‐renewal/differentiation	  balance	  of	  the	  hematopoietic	  stem	  cell,	  the	  
mechanism	   induced	   by	   this	   oncoprotein	   is	   still	   poorly	   understood.	   Previous	   functional	  
proteomic	  studies	  performed	  in	  our	  group	  identified	  the	  molecular	  partners	  of	  the	  native	  AF4	  
protein,	   the	  most	  common	  MLL	   translocation	  partner	   in	   infant	  ALL,	  and	  confirmed	  that	   this	  
protein	  is	  deeply	  involved	  in	  a	  complex	  protein	  network,	   important	  for	  the	  regulation	  of	  the	  
Pol	  II-­‐dependent	  transcription.	  In	  this	  study,	  we	  cloned	  in	  an	  eukaryotic	  expression	  vector	  the	  
complete	   cDNA	   encoding	   MLL-­‐AF4	   and	   transiently	   expressed	   the	   recombinant	   protein	   in	  
Hek293	   cells.	   In	   order	   to	   understand	   which	   molecules	   take	   part	   in	   the	   aberrant	   pathway	  
induced	  by	  the	  MLL-­‐AF4	  oncoprotein,	  we	  aimed	  to	  identify	  some	  of	  its	  molecular	  interactors,	  
starting	  from	  the	  proteins	  that	  are	  already	  known	  to	  interact	  with	  AF4.	  We	  showed	  that	  MLL-­‐
AF4	  binds	  to	  CdK9	  that	  by	   interacting	  with	  cyclin	  T1	  forms	  the	  positive	  elongation	  factor	  (P-­‐
TEFb),	  which	   is	   involved	   in	   the	  activation	  of	   the	  Pol	   II	  elongation	  machinery.	  We	  also	   found	  
that	  MLL-­‐AF4	   interacts	  with	  CRSP130	  and	  CRSP33,	   two	  members	  of	   the	  so-­‐called	  “Mediator	  
Complex”,	  thus	  suggesting	  that	  MLL-­‐AF4	  is	  involved	  in	  the	  regulation	  of	  the	  Pol	  II-­‐dependent	  
transcription.	   Interestingly,	   we	   found	   that	   MLL-­‐AF4	   also	   interacts	   with	   the	   tyrosine-­‐kinase	  
receptor	   FGFR2,	   and	   with	   a	   protein	   belonging	   to	   the	   family	   of	   14-­‐3-­‐3s	   (the	   isoform	   θ),	  
involved	   in	   diverse	   intracellular	   pathways.	   Moreover,	   we	   observed	   down-­‐regulation	   in	   the	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expression	   of	   HoxA9,	   one	   of	   the	   MLL	   target	   genes,	   in	   the	   cells	   co-­‐expressing	   both	  
recombinant	   MLL-­‐AF4	   and	   14-­‐3-­‐3	   θ,	   thus	   suggesting	   that	   this	   interaction	   could	   modulate	  
transcriptional	   processes	   induced	   by	   MLL-­‐AF4.	   Elucidating	   the	   role	   of	   fusion	   protein	  
interactors	  such	  as	  FGFR2	  and	  14-­‐3-­‐3	  θ	  is	  very	  important	  for	  identifying	  new	  molecular	  targets	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Introduction	  
1.1	  Acute	  Lymphoblastic	  Leukemia	  (ALL):	  an	  overview	  
	   All	  different	  types	  of	  blood	  cells	  are	  produced	  in	  the	  bone	  marrow	  starting	  from	  a	  small	  
number	  of	  hematopoietic	  stem	  cells,	  which	  go	  through	  a	  maturation	  process	  to	  give	  rise	  to	  
terminally	  differentiated	  blood	  cells,	  namely,	  red	  cells	  (or	  erythrocytes),	  white	  blood	  cells	  (or	  








Fig.1	   The	   hematopoietic	   cascade.	   Long-­‐term	   haematopoietic	   stem	   cells	   (HSCs)	   have	   the	  
capability	   to	   self-­‐renew	  and	   also	   to	   give	   rise	   to	   all	   the	   cell	   types	  of	   the	  bone	  marrow	  and	  
peripheral	   blood.	   Other	   pluripotent	   progenitors,	   short-­‐term	   HSCs	   and	   multipotent	  
progenitors	   (MPPs)	   have	   less	   self-­‐renewal	   capacity.	   Together,	   these	   three	   cell	   types	  
constitute	  the	  hematopoietic	  stem	  and	  progenitor	  cell	  (HSPC)	  population.	  MPPs	  are	  thought	  
to	  differentiate	   into	   the	  two	  main	  branches	  of	  hematopoietic	  development	   that	  arise	   from	  
the	  common	  lymphoid	  progenitor	  (CLP)	  and	  the	  common	  myeloid	  progenitor	  (CMP)(King	  &	  
Goodell,	  2011).	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   Leukemias	   are	   cancers	   that	   originate	   from	   the	   malignant	   transformation	   of	   blood-­‐
forming	   elements	   at	   various	   stages	   of	   differentiation	   and	   involve	   predominantly	   the	   bone	  
marrow	   and	   peripheral	   blood,	   but	   can	   spread	   to	   other	   parts	   of	   the	   body	   including	   both	  
lymphoid	   (lymph	   nodes,	   spleen)	   and	   non-­‐lymphoid	   (liver,	   central	   nervous	   system,	   skin)	  
organs.	  
	   	   Depending	  on	  the	  cell	  of	  origin,	  leukemias	  can	  be	  subdivided	  in	  acute	  or	  chronic.	  This	  
distinction	  has	  also	  a	  pathological,	  clinical,	  therapeutic	  and	  prognostic	  significance.	  In	  acute	  
leukemia,	   the	  malignant	  cells	   (blasts)	  derive	   from	  very	   immature	  counterparts	  and	   tipically	  
do	  not	  carry	  out	  any	  normal	  functions.	  Usually,	  the	  proliferation	  rate	  is	  extremely	  high,	  and	  
the	   clinical	   course	   is	   very	   aggressive.	   In	   contrast,	   chronic	   leukemia	   is	   characterized	   by	  
preservation	  of	   the	  differentiation	  process	  and	  consequent	  expansion	  of	  mature-­‐appearing	  
cells	   that	  are	  produced	  at	  a	  higher	  rate	  than	  normal	  cells	  and	  accumulate	  over	  time	   in	  the	  
blood;	  for	  this	  reason,	  the	  percentage	  of	  blasts	  in	  the	  bone	  marrow	  and	  peripheral	  blood	  is	  
much	  lower	  compared	  to	  acute	  leukemias.	  	  
	   	   The	   leukemic	   transformation	   can	   involve	   either	   lymphoid	   or	   myeloid	   cells.	  Using	  
these	   two	   parameters	   (acute	   vs	   chronic	   and	   lymphoid	   vs	   myeloid),	   a	   total	   of	   four	   main	  
categories	  are	  identified,	  each	  of	  which	  is	  further	  divided	  into	  different	  subcategories.	  Acute	  
Lymphoblastic	  Leukemia	  (ALL)	  is	  the	  most	  common	  type	  of	  leukemia	  in	  infants.	  	  According	  to	  
the	   morphologic	   characteristics	   of	   the	   lymphoblasts,	   the	   French-­‐American-­‐British	   (FAB)	  
Cooperative	  Working	  Group	  defines	  three	  categories	  of	  ALL:	  	  
• L1:	  lymphoblasts	  are	  small	  cells	  characterized	  by	  a	  high	  nucleus-­‐to-­‐cytoplasm	  ratio.	  
The	  cells	  have	  distinct	  nucleoli	  and	  nuclear	  membranes	  (fig.	  2A);	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• L2:	  lymphoblasts	  are	  larger,	  often	  in	  a	  more	  heterogenous	  population,	  with	  a	  lower	  
nucleus-­‐to-­‐cytoplasm	   ratio,	   prominent	   nucleoli	   and	   nuclear	   membranes	   that	   may	   be	  
reniform	  or	  irregular	  (fig.	  2B);	  	  
• L3	   or	   Burkitt-­‐like	   leukemia:	   lymphoblasts	   are	  morphologically	   heterogeneous	   and	  
characterized	   by	   strongly	   basophilic	   cytoplasm	   and	   prominent	   cytoplasmatic	   vacuolization	  







Fig.2.	   The	   FAB	   classification	   of	   ALL.	   The	   French-­‐American-­‐British	   Cooperative	   Working	  
Group,	  defines	  three	  categories	  of	  lymphoblasts	  and,	  thus,	  three	  different	  types	  of	  ALL	  (L1,	  A;	  
L2,	   B;	   L3,	   C),	   based	   on	   the	   following	   blast	   features:	   nuclear	   cytoplasmic	   ratio;	   presence,	  
prominence	  and	  frequency	  of	  nucleoli;	  regularity	  of	  nuclear	  membrane	  outline,	  and	  cell	  size	  
(Conter	  et	  al,	  2004).	  	  
	  
The	   first-­‐line	   treatment	   currently	   indicated	   for	   ALL	   is	   systemic	   chemotherapy,	  with	  
protocols	   differing	   according	   to	   patient	   age.	   Most	   ALL	   patients	   receive	   a	   combination	   of	  
different	   chemotherapeutic	   drugs.	   The	   most	   active	   agents	   used	   in	   induction	   regimens	  
include	   methotrexate,	   vincristine,	   prednisone,	   asparaginase,	   anthracycline	   and	  
A	  
B	   C	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dexamethasone.	   Mantainance	   chemotherapy	   for	   the	   responding	   patients	   consists	   of	   6-­‐
mercaptopurine,	   cyclophosphamide,	   cytarabine,	   prednisone,	   vincristine,	   carmustine,	  
daunorubicin,	   doxorubicin,	   teniposide	   in	   various	   combinations.	   Prophylactic	   radiation	  
therapy	   to	   the	   central	   nervous	   system	   is	   also	   frequently	   used	   to	   prevent	   or	   delay	   the	  
occurrence	  of	  CNS	  relapse.	  
	  	  
1.2	  	  	  Molecular	  genetics	  of	  ALL	  
In	  most	  cases	  of	  ALL,	  as	  in	  other	  lymphoid	  malignancies,	  a	  single	  damaged	  progenitor	  
cells	   is	   capable	   to	   indefinitely	   expand,	   self-­‐renew	   and	   give	   rise	   to	   malignant	   poorly	  
differentiated	   precursors.	   It	   is	   not	   completely	   clear	   where	   in	   the	   normal	   course	   of	  
differentiation	   the	   “clonal	   event”	   occurs.	   Nowadays,	   thanks	   to	   the	   recent	   development	   of	  
molecular	   cytogenetic	   techniques	   (e.g.	   FISH	   and	   CGH),	   it	   is	   possible	   to	   recognize	  
chromosomal	   abnormalities	   in	   the	   leukemia	   cells	   of	   most	   of	   the	   cases	   of	   pediatric	   ALL	  
(Conter	  et	  al,	  2004).	  	  
Translocations	  are	  the	  most	  commons	  structural	  chromosomal	  changes	   in	  ALL.	  They	  
are	  assumed	  to	  play	  a	  fundamental	  role	  in	  the	  leukemogenic	  process	  and	  in	  most	  cases	  are	  
associated	  with	  elevate	  risk	  of	  early	  treatment	  failure	  (Conter	  et	  al,	  2004).	  
Among	   the	   most	   frequent	   translocations,	   t(9;22)	   is	   the	   most	   one	   associated	   with	  
adult	   ALL	   (Lee,	   2011).	   Moreover,	   chromosomal	   rearrangements	   involving	   TCR	   genes	   are	  
recurrent	   and	   are	   responsible	   for	   the	   aberrant	   or	   ectopic	   expression	   of	   proto-­‐oncogene,	  
some	  of	   them	  being	  directly	  or	   indirectly	   involved	   in	  T-­‐cell	  development,	   such	  as	  NOTCH1,	  
MYB,	  HOXA	  (Graux,	  2011).	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   The	   process	   of	   malignant	   transformation	   in	   pediatric	   acute	   leukemias	   is	   complex,	  
requiring	   at	   least	   two	   leukemogenic	   hits	   that	   result	   in	   DNA	   damage,	   ranging	   from	   point-­‐
mutations	   to	   double-­‐strand	  DNA	   breaks	   leading	   to	   chromosomal	   translocations,	   deletions,	  
duplications	   or	   inversions.	   Investigations	  with	   single	   nucleotide	   polymorphism	   arrays	   have	  
confirmed	   that	   leukemic	   blasts	   have	   multiple	   copy-­‐number	   aberrations	   (Mullighan	   et	   al,	  
2007).	  The	  exception	  seems	  to	  be	  leukemias	  with	  translocations	  involving	  the	  Mixed	  Lineage	  
Leukemia	   gene,	  MLL	   and	   different	   chromosomal	   partners	   that	   are	   rarely	   accompanied	   by	  
other	   genetic	   lesions,	   suggesting	   that	  MLL	   rearrangements	   are	   oncogenic	   events	  with	   the	  
potential	  to	  induce	  leukemia	  in	  a	  single	  hit	  (Szczepanski	  et	  al,	  2010).	  Different	  abnormalities	  
with	  MLL	  involvement	  can	  be	  detected	  in	  almost	  all	  types	  of	  hematological	  malignancies.	  The	  
most	  common	  are	  the	  reciprocal	  translocations	  that	  fuse	  the	  first	  8-­‐11	  coding	  exons	  of	  MLL	  
in	   frame	   to	   a	   partner	   gene	   that	   resides	   on	   a	   different	   chromosome.	   The	   result	   of	   these	  
rearrangements	  is	  the	  production	  of	  an	  oncogenic	  chimeric	  protein	  (Ayton	  &	  Cleary,	  2001).	  
	   Internal	   tandem	   duplications	   within	   the	   MLL	   coding	   region	   have	   been	   described	   in	  
almost	  10%	  of	  adult	  AML	  cases.	  This	  feature	  leads	  to	  an	  elongated	  version	  of	  the	  MLL	  protein	  
where	   the	   N-­‐terminal	   amino	   acid	   sequence	   is	   duplicated	   and	   fused	   to	   itself	   in	   a	   tandem	  
repeat.	  The	  presence	  of	  this	  kind	  of	  rearrangement	  in	  AML	  most	  likely	  also	  worsens	  disease	  
outcome	  (Dohner	  et	  al,	  2002;	  So	  et	  al,	  1997;	  Yu	  et	  al	  1996).	  
	   The	  unaltered	  MLL	  gene	  itself	  can	  be	  amplified	  in	  samples	  of	  AML	  and	  myelodysplastic	  
syndrome	   suggesting	   that	   an	   increase	   of	   the	   MLL	   gene	   dosage	   might	   evoke	   similar	  
downstream	  effects	  like	  the	  presence	  of	  an	  MLL	  fusion	  or	  PTD	  11	  (Dolan	  et	  al,	  2002;	  Poppe	  et	  
al,	  2004).	  
	   However,	  most	  MLL	  rearrangements	  are	  due	  to	  reciprocal	  chromosome	  translocations	  
that	  link	  MLL	  to	  any	  of	  more	  than	  100	  partner	  genes	  (Meyer	  et	  al,	  2009).	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   The	  partner	  proteins	  most	  commonly	  found	  associated	  with	  MLL	  (AF4,	  AF9,	  ENL,	  AF10,	  
ELL)	  are	  transcriptional	  elongation	  factors	  (Bitoun	  et	  al,	  2007).	  Since	  these	  factors	  physically	  
associate,	   the	   partner	   of	   MLL	   within	   the	   fusion	   proteins	   seems	   to	   recruit	   the	   other	  
elongation	   factors	   and	   thereby	   augmenting	   the	   target	   genes	   transcription	   (Mueller	   et	   al,	  
2009).	   Despite	   the	   large	   number	   of	   its	   partners,	   all	   MLL	   fusions	   are	   invariably	   formed	  
according	   to	   the	   same	  pattern:	   the	  C-­‐terminus	  of	  MLL	   is	   replaced	   in	   frame	  by	   the	  protein	  
partner.	  The	  partner	  proteins	  frequently	  contain	  activation	  domains	  in	  their	  C-­‐terminus,	  and	  
consequently,	   the	   C-­‐terminal	  minimal	   transactivator	   domain	   suffices	   to	   convert	  MLL	   to	   an	  
active	  oncoprotein	  (Slany,	  2005).	  	  
	  
The	  Mixed	  Lineage	  Leukemia	  (MLL)	  gene	  and	  protein	  
The	  long	  arm	  of	  chromosome	  11	  was	  long	  noted	  by	  onco-­‐hematologists	  as	  a	  hotspot	  
for	   genomic	   rearrangements.	   In	   particular	   the	   cytogenetic	   band	   11q23	   became	   notorious	  
because	   alterations	   of	   this	   locus	   were	   associated	   with	   especially	   aggressive	   leukemias	  
(Esseltine	  et	  al,	  1982;	  Kaneko,	  1982).	  
Nowadays	  we	  know	  that	  this	   is	  because	  11q23	  harbors	  the	  Mixed	  Lineage	  Leukemia	  
gene	  (MLL,	  known	  also	  as	  HRX	  or	  ALL-­‐1)	  and	  abnormalities	  at	  11q23	  frequently	  convert	  MLL	  
to	  an	  active	  oncogene	  (Slany,	  1995).	  
	   MLL	  is	  a	  member	  of	  an	  evolutionarily	  conserved	  family	  of	  proteins	  known	  as	  "the	  
trithorax	   group"	   (trxG),	   which	   are	   positive	   regulators	   of	   gene	   expression	   during	   the	  
development.	   Indeed,	   trxG	   proteins	   are	   involved	   in	   the	   so-­‐called	   “cellular	   memory”.	   This	  
epigenetic	   mechanism	   is	   necessary	   in	   development	   and	   differentiation	   whenever	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transcriptional	  patterns	  must	  be	  heritably	  fixed	  for	  future	  cell	  generations,	  also	  in	  absence	  of	  
the	  initially	  determining	  transcription	  factors	  (Slany,	  2005).	  
	   The	  MLL	   genomic	   structure	   consists	   of	   36	   exons	   distributed	   over	   100	   kb	   and	  
produces	   a	   12-­‐kb	   mRNA	   that	   encodes	   a	   3969	   amino	   acid	   protein	   with	   an	   estimated	  
molecular	  weight	  of	  430	  kDa	  (Aplan,	  2006).	  Three	  main	  domains	  have	  been	  implicated	  in	  the	  
MLL	  function:	  the	  AT	  hooks	  motifs,	  which	  bind	  within	  the	  minor	  groove	  of	  the	  double	  helix;	  a	  
region	  homologous	  to	  DNA	  methyltransferase	  (DNMT),	  which	  binds	  to	  non-­‐methylated	  CpG	  
dinucleotides	  –	  a	  feature	  characteristic	  of	  CpG	  islands	  in	  transcriptionally	  competent	  genes;	  
and	  a	  highly	  conserved	  H3K4	  methyltransferase	  (SET)	  domain,	  which	  methylates	   lysine	  4	   in	  








Fig.	  3.	  Schematic	  representation	  of	  the	  most	  relevant	  functional	  domains	  in	  the	  wild-­‐type	  
MLL	  protein.	  Starting	   from	  the	  N-­‐terminus	  portion	  of	   the	  MLL	  protein,	   there	  are	  three	  AT-­‐
hooks	  motifs,	  two	  Nuclear	  Localization	  Signals	  (NLS),	  two	  Transcriptional	  Repression	  domains	  
(TRD),	   three	   Plant	   Homeo	   Domain	   (PHD)	   fingers,	   the	   FYRN	   region,	   the	   Transactivation	  
Domain	  (TAD),	  the	  FYRC	  region	  and	  the	  SET	  domain.	  
	  
Between	  the	  AT	  hooks	  and	  a	  large	  transcriptional	  repression	  domain	  (TRD1+TRD2)	  there	  
are	  two	  small	  regions,	  NLS1	  and	  NLS2,	  which	  specify	  the	  subnuclear	  localization	  of	  the	  MLL	  
protein	   (Slany	   et	   al,	   1998).	   TRD1	   contain	   the	   DNA	   methyltransferase	   homology	   domain,	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DNMT1,	   including	   the	   CXXC	   zinc	   finger	   domain	   (Zeleznik-­‐Le	   et	   al,	   1994)	   whereas	   TRD2	  
mediates	  transcriptional	  repression	  through	  recruitment	  of	  the	  histone	  deacetylases	  HDAC1	  
and	   HDAC2,	   which	   can	   also	   interact	   with	   part	   of	   TRD1	   directly	   (Xia	   ZB	   et	   al,	   2003).	   The	  
mature	  MLL	  protein	   is	   cleaved	  by	  a	   specific	  protease	  which	  cuts	   the	  protein	  at	  amino	  acid	  
residues	   2666/2667	   and	   2718/2719.	   The	   enzyme	   responsible	   of	   this	   proteolitic	   event	   is	  
called	   taspase	  1,	   a	   threonine	  protease	   that	   cleaves	  MLL	   into	  N300/320	   and	  C180	   terminal	  
polypeptides	  (Hsie	  et	  al,	  2003).	  Both	  parts	  are	  associated	  through	  the	  FYRN	  domain	  (aa	  2023-­‐
2073)	  and	  FYRC	  domain	  plus	  part	  of	  the	  SET	  domain	  (aa	  3666-­‐3876)	  (Daser	  &	  Rabbitts,	  2007).	  
The	  FYR	  domains	  are	  defined	  as	  40-­‐90	  aminoacids-­‐long	  sequences	  rich	   in	  phenylalanine	  (F)	  
and	  tyrosine	  (Y)	  residues	  (Pless	  et	  al,	  2011).	  Three	  PHD	  zinc	  finger	  domain	  are	  present	  in	  the	  
N-­‐terminus	  portion	  of	  MLL	  that	  is	  lost	  after	  the	  translocation	  event.	  The	  third	  PHD	  has	  been	  
found	   to	   interact	   with	   the	   nuclear	   cyclophilin	   CYP33	   and	   this	   interaction	   seems	   to	   affect	  
HOXC8	   and	   HOXC9	   transcription	   (Fair	   et	   al,	   2001).	   The	   transcriptional	   activation	   domain	  
(TAD)	  is	  not	  found	  in	  Drosophila	  trithorax,	  but	  it	  is	  conserved	  in	  vertebrate	  MLL-­‐homologues	  
and	  binds	  directly	  to	  the	  co-­‐activator	  CBP	  (CREB-­‐binding	  protein)	  (Bannister	  et	  al,	  1996).	  	  
	  
MLL	  regulates	  the	  Hox	  genes	  expression	  
In	  mammals,	  MLL	  positively	   regulates	   the	   clustered	  homeobox	   (Hox)	   genes	   and	   the	  
homeobox	  cofactor	  MEIS1,	  which	  play	  a	  key	  role	   in	  hematopoietic	  differentiation	  (Milne	  et	  
al,	  2002).	  Overexpression	  of	  individual	  Hox	  genes	  is	  leukemogenic	  in	  mice	  (Kroon	  et	  al,	  1998).	  
Normally,	  Hox	  expression	  is	  high	  in	  hematopoietic	  stem	  cells	  and	  gradually	  decreases	  during	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differentiation.	   Failure	   to	   downregulate	  Hox	   expression	   inhibits	   hematopoietic	  maturation	  
and	  can	  lead	  to	  leukemia	  (Thorsteinsdottir	  et	  al,	  2002).	  	  
The	   H3K4	   methylation	   status	   of	   the	   chromatin	   correlates	   with	   an	   active	   state	   of	  
transcription,	  so	   it	   is	   likely	  the	  HOX	  gene	  promoters	  are	  H3K4	  methylated	  through	  the	  MLL	  
SET	   domain	   (Daser	   &	   Rabbitts,	   2007).	   However,	   Milne	   et	   al	   (2002)	   demonstrated	   that,	  
although	  the	  leukemogenic	  MLL-­‐AF9	  fusion	  lacks	  the	  SET	  domain,	  it	  can	  still	  activate	  HoxC8	  
without	  H3K4	  methylation	  activity.	  
	   Data	   from	   ChIP-­‐seq	   analysis	   revealed	   that	  MEIS1,	   HOXA7,	   HOXA9	   and	   HOXA10	   are	  
among	  the	  226	  primary	  targets	  of	  MLL-­‐AF4	  in	  a	  human	  ALL	  cell	   line	  (Guenther	  et	  al,	  2008).	  
Interestingly,	  Orlovsky	  et	  al	   (2011)	   found	   that	  downregulation	  of	  MEIS1	  and	  HOXA	   in	  MLL-­‐
rearranged	   acute	   leukemia	   impairs	   engraftment	   and	   reduces	   the	   proliferation	   of	   the	  
transformed	  cells.	  
	  
The	  AF4	  gene	  and	  protein	  
	   The	   AF4	   gene,	   also	   known	   as	   FEL,	   was	   first	   described	   as	   the	   most	   frequent	   fusion	  
partner	  with	  MLL	  in	  the	  infant	  acute	  lymphoblastic	  leukemia	  (Gu	  et	  al,	  1992)	  and	  encodes	  a	  
transcriptional	   activator	   implicated	   in	   lymphopoiesis	   and	   Purkinje	   cell	   function	   in	   the	  
cerebellum	  (Bitoun	  et	  al,	  2007).	  	  
	   The	  AF4	  gene	  localizes	  on	  4q21	  cytogenetic	  band,	  spans	  134050	  bp	  and	  consists	  of	  20	  
exons.	  Its	  mature	  transcript	  is	  9290	  bp	  long,	  the	  length	  of	  its	  ORF	  is	  3633	  bp	  and	  is	  translated	  
in	  a	  1210	  aa-­‐long	  protein,	  with	  a	  molecular	  weight	  of	  140	  kDa.	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   Northern	   Blot	   experiments	   found	   that	   AF4	   mRNAs	   are	   widely	   expressed	   in	  
hematopoietic	  cells	  and	  tissues	  (Chen	  et	  al,	  1993).	  Moreover,	  the	  lymphoid	  nuclear	  protein	  
related	   to	   AF4	   (LAF4),	   isolated	   from	   Burkitt’s	   lymphoma,	   shares	   high	   degree	   of	   sequence	  
homology	   with	   AF4	   and	   it	   showed	   to	   possess	   DNA	   binding	   ability,	   thus	   hypothesizing	   a	  
potential	  role	  as	  a	  transcriptional	  activator	  (Ma	  &	  Staudt,	  1996).	  AF4	  and	  LAF4,	  together	  with	  
AF5q31	  and	  FMR2	  belong	  to	  the	  so-­‐called	  “ALF”	   family	  and	  share	  three	  conserved	  regions:	  
the	   N-­‐terminal	   homology	   domain,	   the	   ALF	   domain,	   which	   contains	   a	   serine/proline	   rich	  
region	  containing	  GTP-­‐binding	  domain,	  and	  the	  C-­‐terminal	  homology	  domain.	  Furthermore,	  
each	  member	   of	   the	  ALF	   family,	   except	   FMR2,	   has	   a	   transactivation	  domain	   (Prasad	   et	   al,	  
1995).	  The	  ALF	  domain	   seems	   to	  promote	   the	  protein	  proteasome-­‐dependent	  degradation	  
by	  mediating	  its	  interaction	  with	  SIAH	  (seven	  in	  absentia	  homologue)	  ubiquitin	  ligase	  (Oliver	  
et	   al,	   2004;	  Bursen	  et	   al,	   2004).	  As	   a	   further	   confirmation	   that	  AF4	  works	   a	   transactivator	  
factor,	   Li	   et	   al	   (1998)	   showed	   that	   AF4	   localize	   into	   the	   nucleus,	   because	   of	   its	   nuclear	  
targeting	  sequences.	  	  
	   A	   murine	   AF4-­‐knockout	   model	   demonstrated	   that	   AF4	   is	   important	   for	   normal	  
lymphocyte	  development	  and	  cell	  growth	  (Isnard	  et	  al,	  2000).	  AF4	  was	  also	  identified	  as	  the	  
disease	  gene	  in	  the	  robotic	  mouse,	  a	  dominant	  N-­‐ethyl-­‐N-­‐nitrosurea	  mutant	  that,	  besides	  the	  
defect	  in	  early	  T-­‐cell	  maturation	  develops	  ataxia	  because	  of	  Purkinje	  cell	  degeneration	  in	  the	  
cerebellum	  (Isaacs	  et	  al,	  2003;	  Bitoun	  &	  Davies,	  2005).	  Furthermore,	  AF4	  was	  found	  to	  have	  
transcriptional	   regulatory	   properties	   that	   entail	   elongation	   and	   chromatin	   remodeling	  
involving	   Pol	   II,	   also	   through	   the	   interaction	   with	   the	   P-­‐TEFb	   complex,	   ENL	   and/or	   AF9	  
(Erfurth	  et	  al,	  2004).	  Notably,	  AF4	  associate	  with	  Dot1L,	  the	  histone	  methyltranseferase	  that	  
modify	  H3K79	  and	  marks	  actively	  transcribed	  genes	  (Bitoun	  et	  al,	  2007).	  Recently,	  Yokoyama	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et	   al	   (2010)	   demonstrated	   that	   AF4	   takes	   part	   to	   a	   higher-­‐order	   complex,	   which	   is	  
constituted	   by	   P-­‐TEFb,	   ENL,	   AF5q31	   (AEP	   complex),	   and	   that	   this	   complex	   is	   recruited	   by	  
wild-­‐type	  MLL	  on	  its	  target	  promoters	  (i.e.	  HOXA9	  and	  MEIS1).	  Thus,	  it	  seems	  that	  chimaeric	  
proteins	   originating	   from	   the	   fusion	   of	   MLL	   to	   one	   of	   the	   AEP	   components,	   could	  
constitutively	   form	  hybrid	   complexes,	   that	   cause	   sustained	  expression	  of	  MLL-­‐target	  genes	  






Fig.4.	  A	  complex	  containing	  AF4	  and	  ENL	  family	  proteins	  with	  P-­‐TEFb	  facilitates	  oncogenic	  
and	  physiologic	  MLL-­‐dependent	  transcription.	  Many	  of	  the	  nuclear	  MLL	  fusion	  partners	  are	  
connected	   in	   a	   complex	   that	   is	   associated	   with	   chromatin	   modifications	   imposed	   during	  
transcriptional	  elongation.	  Methylation	  of	  histone	  H3	  lysine	  K79	  and	  phosphorylation	  of	  the	  




The	  t(4;11)	  chromosomal	  translocation	  produces	  an	  active	  fusion	  oncoprotein,	  
MLL-­‐AF4	  
	   The	  MLL	  gene	  participates	   in	  a	   large	  variety	  of	  different	  chromosomal	   translocations,	  
that	   result	   in	   the	   production	   of	   chimaeric	   oncoproteins,	   which	   initiate	   critical	   steps	   of	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malignant	   transformation	   and	   lead	   either	   to	   the	   development	   of	   AML	   or	   ALL	   Leukemia.	  
However,	   the	   aberrant	   molecular	   mechanism	   induced	   by	   the	   fusion	   proteins	   remains	  
unclear.	  	  
	   To	  date,	   over	  90%	  of	   the	   leukemias	  diagnosed	   in	  newborns/infants	   (<1	   year	  old)	   are	  
pro-­‐B	   stage	   acute	   lymphoblastic	   leukemias	   harboring	   the	   leukemic	   fusion	   gene	   MLL-­‐AF4	  
(Bueno	   et	   al,	   2011).	   This	   translocation	   is	   the	   hallmark	   of	   a	   high-­‐risk	   acute	   lymphoblastic	  
leukemia	  (ALL),	  which	  has	  a	  particularly	  poor	  prognosis	  in	  infants	  (Pui	  et	  al,	  2002).	  	  
	   Although	  most	  evidence	  reported	  that	  the	  oncogenic	  properties	  reside	  in	  the	  MLL-­‐AF4	  
product,	  there	  are	  some	  data	  demonstrating	  that	  the	  combined	  effects	  of	  the	  two	  reciprocal	  
t(4;11)	   fusion	   proteins	   MLL-­‐AF4	   and	   AF4-­‐MLL	   confer	   resistance	   to	   apoptosis,	   cell	   cycling	  
capacity	   and	   growth	   transformation	   (Gaussmann	   et	   al,	   2007).	   Moreover,	   the	   same	   group	  
showed	   that	   the	   AF4-­‐MLL	   fusion	   protein	   is	   capable	   of	   inducing	   ALL	   in	   mice	   without	  
requirement	  of	  MLL-­‐AF4	   (Bursen	  et	  al,	  2010).	   In	   contrast	  Kumar	  et	  al	   (2010)	  have	   recently	  
demonstrated	   that	   the	   loss	   of	   AF4-­‐MLL	   had	   no	   effect	   on	   the	   growth	   of	   either	   RS4;11	   or	  
SEMK2-­‐M1	  cells,	  which	  express	  both	   reciprocal	   fusion	  products.	   Indeed	   in	   SEMK2-­‐M1	  cells	  
there	  were	  no	  changes	  in	  cell	  cycle	  or	  apoptosis	  with	  loss	  of	  AF4-­‐MLL,	  whereas	  knockdown	  of	  
MLL-­‐AF4	  significantly	  inhibited	  growth	  of	  both	  RS4;11	  and	  SEMK2-­‐M1.	  
The	  MLL-­‐AF4	   fusion	   site	   differs	   among	   t(4;11)-­‐positive	   cell	   lines.	   Indeed,	   SEM	   cells	  
express	  a	  transcript	  in	  which	  exon	  9	  of	  MLL	  is	  fused	  to	  exon	  4	  of	  AF4,	  whereas	  RS4;11	  cells	  
express	  an	  e10-­‐e4	  variant	   (Stong	  et	  al,	  1985;	  Thomas	  et	  al,	  2005).	   In	  our	   research	  group	  a	  
hitherto	  unknown	  MLL-­‐AF4	  breakpoint	  was	  identified,	  in	  which	  the	  sequences	  corresponding	  
to	  MLL	  exon	  9	  are	  fused	  with	  the	  sequences	  corresponding	  to	  exon	  11	  of	  the	  AF4	  gene	  in	  the	  
fusion	   transcript.	   The	   predicted	   structure	   of	   the	   new	  MLL-­‐AF4	   chimeric	   protein	   lacks	   the	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portion	  of	  the	  AF4	  transactivation	  domain,	  spanning	  residues	  480	  to	  560,	  which	  is	  encoded	  
by	  exon	  10	  of	  the	  AF4	  gene	  and	  the	  first	  nucleotides	  of	  exon	  11	  (Pane	  et	  al,	  2002)	  (Fig.	  5).	  	  
Following	   the	   t(4;11)	   translocation,	   genomic	   sequences	   encoding	   the	   AT-­‐hook	   and	  
proline-­‐rich	  regions	  of	  MLL	  are	  fused	  in-­‐frame	  to	  the	  AF4	  sequence	  that	  encodes	  the	  NLS	  and	  
GTP-­‐binding	   activity,	   thereby	   resulting	   in	   a	   chimeric	   mRNA	   of	   12.5	  kb	   that	   encodes	   a	  
predicted	  fusion	  protein	  of	  240	  kDa	  (Li	  et	  al,	  1998).	  
	  
Fig.	   5.	   Different	   breakpoints	   and	   different	   fusion	   proteins	   MLL-­‐AF4.	   Although	   the	   most	  
frequent	  MLL-­‐AF4	  breakpoint	  consists	  in	  the	  in-­‐frame	  fusion	  of	  exon	  9	  of	  MLL	  and	  the	  exon	  4	  
of	   AF4	   (“usual”),	   many	   other	   different	   breakpoints	   are	   known	   and	   characterized	   in	   the	  
t(4;11)	  ALL	  patients.	  The	  one	  we	  called	  “novel”	  consisted	  in	  the	  fusion	  of	  exon	  9	  of	  MLL	  and	  
the	  exon	  11	  of	  AF4,	  thus	  skipping	  a	   large	  sequence	  encoding	  the	  transactivation	  domain	  of	  
the	  AF4	  protein.	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Although	  the	  MLL	  fusion	  proteins	  lack	  the	  SET	  domain	  of	  MLL,	  they	  retain	  the	  ability	  
to	  bind	  Hox	  genes	  and	  other	  promoters	  (Krivstov	  et	  al,	  2008).	  The	  mechanisms	  by	  which	  MLL	  
fusions	  may	  deregulate	  gene	  expression	   include	   the	   recruitment	  of	  a	  protein	  complex	   that	  
could	  induce	  an	  abnormal	  activity	  of	  histone	  modification.	  For	  example,	  Bitoun	  et	  al	  (2007)	  
demonstrated	   that	   AF4	   belongs	   to	   a	   transcriptional	   regulatory	   chromatin	   remodeling	  
complex,	  as	  well	  as	  AF9,	  ENL	  and	  AF10	  proteins,	  which	  are	  also	   implicated	  in	   leukemia	  and	  
human	  neurological	  dysfunctions.	  They	  provide	  evidence	  that	  these	  proteins	  collaboratively	  
function	   as	   positive	   regulators	   of	   gene	   transcription	   by	   stimulating	   p-­‐TEFb	   kinase	   activity.	  
They	  also	  mediate	  Dot1-­‐dependent	  methylation	  of	  H3-­‐K79,	  thereby	  facilitating	  the	  transition	  
of	   Pol	   II	   into	   productive	   elongation	   and	   its	   progression	   along	   the	   DNA	   template	   by	  
maintaining	   the	   chromatin	   structure	   in	   an	   open	   conformation.	   Krivstov	   et	   al	   (2008)	  
demonstrated	  that	  the	  H3K79	  methylation	  is	  enhanced	  at	  many	  loci	  in	  leukemia	  cells	  from	  a	  
murine	  model	  of	  MLL-­‐AF4	  and	  in	  human	  MLL-­‐AF4	  leukemia	  cells,	  and	  showed	  that	  enhanced	  
methylation	   is	   correlated	   with	   increased	   gene	   expression.	   The	   suppression	   of	   H3K79	  
methylation	  leads	  to	  inhibition	  of	  gene	  expression	  in	  MLL-­‐AF4	  cells.	  	  
Previous	  data	  obtained	  in	  our	  research	  group	  showed	  that	  the	  native	  AF4	  protein	   is	  
part	   of	   a	   large	   network	   of	   molecular	   interactions	   involved	   in	   the	   regulation	   of	   the	   RNA-­‐
Polymerase	  II	  transcriptional	  machinery	  (Esposito	  et	  al,	  2011).	  	  
	  
The	  t(4;11)	  rearrangement	  occurs	  in	  an	  early	  hematopoietic	  progenitor	  cell	  
	   A	   large	   body	   of	   evidence	   suggests	   that	   high	   risk	   t(4;11)	   (q21;	   q23)	   ALL	   originates	   in	  
primitive	   lymphoid-­‐restricted	  CD34+C19-­‐	   stem	   cells	   thereby	   supporting	   the	   hypothesis	   that	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the	  poor	  outcome	  is	  a	  consequence	  of	  the	  transformation	  of	  a	  primitive	  stem/progenitor	  cell	  
(Hotfilder	  et	  al,	  2005).	  	  
	   Furthermore,	  Montes	  et	  al	  (2011)	  showed	  that	  the	  enforced	  expression	  of	  MLL-­‐AF4	  in	  
human	   cord	   blood-­‐derived	   hematopoietic	   stem	   and	   progenitor	   cells	   enhances	   the	  
hematopoietic	   repopulating	   cell	   function	   and	   clonogenic	   potential.	   However,	   these	   events	  
seem	   to	   be	   not	   sufficient	   for	   initiating	   leukemogenesis	   in	   vivo.	   This	   inability	   to	   develop	   a	  
MLL-­‐AF4+	   ALL	   disease	  model	   based	   on	   human	   cord-­‐blood-­‐CD34+	   progenitors	   suggests	   that	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Materials	  and	  Methods	  	  
Cloning	  procedure	  of	  cDNAs	  encoding	  MLL-­‐AF4	  	  
Because	   of	   the	   wide	   length	   of	   the	   usualMLL-­‐AF4	   fusion	   cDNA	   (6.681	   kb),	   we	   decided	   to	  
amplify	   the	  cDNA	   in	  3	  different	  overlapping	   fragments,	  by	  using	  primer	  pairs,	  each	  specific	  
for	   the	   following	   fragments:	   “MAF1-­‐2-­‐3”,	   containing	   nt	   1-­‐3725	   of	   MLL;	   “usualMLL-­‐AF4	  
breakpoint”,	  from	  nt	  3726	  to	  5137	  of	  MLL;	  “AF4”,	  the	  portion	  of	  AF4	  that	  takes	  part	   in	  the	  
chimaera,	   nt	   1040-­‐3635	   of	   AF4.	   The	   MAF1-­‐2-­‐3	   fragment	   was	   subdivided	   in	   3	   further	  
fragments:	  MAF1,	  MAF2	  and	  MAF3.	  
RNA	  extraction	  
Total	   RNA	   was	   extracted	   from	   RS4;11	   cells	   with	   TRIzol	   (Invitrogen),	   according	   to	   the	  
manufacturer’s	  instructions.	  The	  RNA	  was	  resuspended	  in	  H20	  and	  stored	  at	  -­‐80	  °C.	  
Reverse	  Transcriptase-­‐Polymerase	  Chain	  Reaction	  (RT-­‐PCR)	  
RT-­‐PCR	   was	   carried	   out	   by	   using	   “SuperScriptTM	   III	   Reverse	   Transcriptase”	   (Invitrogen)	   kit,	  
with	  “Random	  Primers”	  (Invitrogen),	  following	  the	  manufacturer’s	  instructions.	  5	  µg	  of	  RNA	  
was	   used	   as	   template	   for	   the	   RT	   reaction.	   The	   cDNA	  was	   amplified	   by	   using	   primer	   pairs	  
specific	  for:	  MAF1,	  MAF2,	  MAF3	  and	  usualMLL-­‐AF4	  breakpoint.	  100	  ng	  of	  cDNA	  were	  used	  as	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Topo-­‐Cloning	  
Each	  PCR	  product	  was	  cloned	   in	  the	  pCRII-­‐TOPO	  entry	  vector	   (Invitrogen),	  according	  to	  the	  
manufacturer’s	   procedure.	   This	   vector	   provides	   the	   direct	   insertion	   of	   an	   amplified	   PCR	  
product	  without	  digestion	  and	  ligation	  procedures.	  This	  procedure	  bases	  on	  the	  Taq	  terminal	  
transferase	  activity	  that	  adds	  a	  single	  deoxyadenosine	  (A)	  to	  the	  3’	  ends	  of	  PCR	  products.	  The	  
pCRII-­‐TOPO	  has	  single	  overhanging	  3’	  deoxythymidine	  (T)	  residue,	  which	  allows	  PCR	   inserts	  
to	  ligate	  efficiently	  with	  the	  vector.	  
	  
Cloning	  of	  MLL-­‐AF4	  in	  p3XFlag	  
For	  the	  cloning	  of	  MLL-­‐AF4,	  we	  chose	  the	  p3XFlag	   (Sigma)	  as	  eukaryotic	  expression	  vector.	  
This	  plasmid	  provides	  three	  adjacent	  FLAG	  epitopes	  upstream	  of	  the	  multiple	  cloning	  region.	  
The	   presence	   of	   this	   epitope,	   which	   is	   easily	   recognized	   by	   a	   specific	   antibody	   anti-­‐FLAG,	  
allows	  to	  facilitate	  the	  detection	  and	  purification	  procedures	  of	  the	  protein	  of	  interest.	  
In	  order	  to	  introduce	  the	  fusion	  MLL-­‐AF4	  cDNA	  in	  the	  p3XFlag,	  we	  first	  amplified	  the	  single	  
MAF1,	   MAF2	   and	   MAF3	   sequences	   from	   the	   “pCRII-­‐TOPO+MAF1”,	   “pCRII-­‐TOPO+MAF2”,	  
“pCRII-­‐TOPO+MAF3”	   constructs,	   respectively,	   by	   using	   primer	   pairs,	   containing	   sequences	  
recognized	  by	  specific	  enzymes,	  at	  their	  5’	  end.	  Then,	  by	  performing	  series	  of	  digestion	  and	  
cloning	   of	   the	   three	   overlapping	   fragments,	   we	   obtained	   the	   product	   MAF1-­‐2-­‐3	   in	   the	  
p3XFlag.	  
The	   usualMLL-­‐AF4	   breakpoint	   fragment	   was	   first	   amplified	   from	   the	   cDNA	   with	   specific	  
primer	  pairs,	  containing	  the	  specific	  sites	  recognized	  by	  EcoRI	  and	  XbaI	  at	  their	  5’	  ends,	  from	  
the	  pCRII-­‐TOPO+usualMLL-­‐AF4	  breakpoint.	  Then,	  both	  insert	  and	  p3XFlag	  were	  digested	  with	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EcoRI	   and	   XbaI.	   The	   digestion	   products	   were	   loaded	   on	   0.8%	   agarose	   gel	   and	   purified	   by	  
“QIAquick	   gel	   extraction	   kit”	   (Qiagen).	   The	   ligation	   reaction	   was	   performed	   at	   a	   molar	  
concentration	  of	  1:2	  (vector	  :	  insert),	  by	  following	  the	  Ligafast	  Protocol	  (Promega).	  
100	  µl	  of	  TOP10	  strain	  of	  E.	  coli	  cells	  were	  transformed	  in	  sterile	  conditions	  with	  10	  µl	  of	  the	  
ligation	  products	  and	  kept	  on	  ice	  for	  20’.	  Then	  the	  suspension	  was	  incubated	  at	  42°C	  for	  45”	  
and	  then	  at	  37°C	  for	  45’,	  following	  the	  adding	  of	  250	  µl	  of	  Luria-­‐Bertani	  (LB)	  broth.	  Then,	  the	  
suspension	  was	  spread	  on	  a	  LB+agar	  plate,	  containing	  the	  antibiotic	  ampicillin	  [100	  mg/ml].	  
Indeed,	   thanks	   to	   the	   ampicillin	   resistance	   gene,	   encoded	   by	   the	   p3XFlag,	   it	   was	   possible	  
select	  only	  the	  cloning	  positive	  colonies,	  after	  the	  O.N.	  incubation	  of	  the	  plate	  at	  37°C.	  Some	  
colonies	  were	  picked	   and	   cultured	   in	   LB+ampicillin	   at	   37°C	  O.N.,	   in	   order	   to	   obtain	   a	   high	  
amount	  of	  plasmids.	  The	  plasmidic	  DNA	  was	  purified	  from	  the	  bacterial	  suspension,	  by	  using	  
the	   “Plasmid/Cosmid	   purification	   kit”	   (Qiagen).	   The	   plasmids	   were	   tested	   by	   restriction	  
digestion	   and	   sequenced	   at	   the	   Core	   Facility	   for	   DNA	   Sequencing	   of	   Ceinge-­‐Biotecnologie	  
Avanzate.	  	  
	  
Reproduction	  of	  the	  novelMLL-­‐AF4	  breakpoint	  
The	   novel	  MLL-­‐AF4	   breakpoint	  was	   obtained	   from	   the	   usualMLL-­‐AF4	   cDNA,	   by	   a	   series	   of	  
amplification	  and	  ligation	  procedures,	  as	  described	  below.	  
Two	   primer	   pairs	   (A	   and	   B)	  were	   designed	   both	   upstream	   and	   downstream	   to	   the	   known	  
different	  portion	  among	  the	  usual	  and	  the	  novel	  breakpoint	   (the	  blue	  portion	   in	   fig.6).	  The	  
two	   regions	   were	   amplified	   by	   PCR	   and	   then,	   the	   PCR	   products	   were	   blunt-­‐ligated.	   The	  
Forward	  A	  and	  the	  Reverse	  B	  were	  used	  for	  the	  amplification	  of	  the	  whole	  region	  “novelMLL-­‐
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AF4”	   breakpoint.	   The	   PCR	   product	   was	   then	   digested	   with	   EcoRI	   and	   XbaI,	   and	   cloned	   in	  














Fig.	   6.	   Reproduction	   of	   the	   cDNA	   encoding	   “novelMLL-­‐AF4	   breakpoint”.	   The	   “novel”	  
breakpoint	   is	   ~	   700	  bp	   smaller	   than	   the	  usual	   one.	   The	  procedure	   for	   reproduction	  of	   the	  
novel	   breakpoint	   consisted	   in	   the	   amplification	   of	   the	   regions	   immediately	   upstream	   and	  
downstream	   to	   the	  different	   sequence	  between	   the	   two	  breakpoints	   (the	  blue	   region),	   by	  
using	  specific	  oligonucleotide	  sequences	  (forward	  A	  and	  reverse	  A	  for	  the	  upstream	  region;	  
forward	   B	   and	   reverse	   B	   for	   the	   downstream	   sequence).	   The	   two	   amplicons	   (A	   and	   B)	  
obtained	   from	   the	   “usual”	   breakpoint	   were	   than	   undergone	   to	   ligation	   reaction	   and	  
amplified	  by	  using	  forward	  A	  and	  reverse	  B	  primers.	  
	  
LIGATION	  
Usual	  MLL-­‐AF4	  breakpoint	  
Novel	  MLL-­‐AF4	  breakpoint	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The	  p3XFlag+AF4	  full	  length,	  already	  obtained	  in	  our	  lab	  for	  previous	  experiments,	  was	  used	  
for	   obtaining	   the	   whole	   usual/novel	   MLL-­‐AF4	   clones.	   5	   µg	   of	   this	   plasmid	   was	   used	   as	  
destination	  vector	  and	  digested	  with	  NotI	  and	  PstI	  (Roche),	  thus	  removing	  all	  the	  N-­‐terminus	  
AF4	  portion	  not-­‐included	  in	  the	  MLL-­‐AF4	  fusion.	  Then,	  both	  usualMLL-­‐AF4	  and	  novelMLL-­‐AF4	  
breakpoint	  were	  excised	  by	  digesting	   the	  p3XFlag+usual/novelMLL-­‐AF4	  constructs	  with	   the	  
same	   enzymes	   and	   inserted	   in	   the	   destination	   vector,	   by	   ligation	   reaction,	   as	   already	  
described.	  
Finally,	   6	   µg	   of	   both	   p3XFlag+MAF1-­‐2-­‐3	   and	   p3XFlag+usual/novelMLL-­‐AF4	   were	   digested	  
with	  NotI	  and	  BamHI.	  The	  linear	  fragment	  of	  ~3	  kb	  originating	  from	  the	  latter	  reaction,	  was	  
ligated	  with	  MAF1-­‐2-­‐3,	  originated	  from	  the	  first	  digestion,	  according	  with	  the	  same	  Ligation	  
protocol	  (Promega),	  already	  described.	  Some	  colonies	  “p3XFlag+MAF1-­‐2-­‐3+usual/novelMLL-­‐
AF4”	   were	   tested	   by	   restriction	   digestion	   and	   sequenced	   at	   the	   Core	   Facility	   for	   DNA	  
Sequencing	  of	  Ceinge-­‐Biotecnologie	  Avanzate.	  	  
	  
Cloning	  of	  cDNA	  encoding	  MLL-­‐AF4	  in	  a	  tet-­‐on	  system	  
In	  order	  to	  obtain	  a	  regulated	  expression	  of	  MLL-­‐AF4,	  the	  tetO/mEPO	  plasmid	  was	  used	  as	  
destination	   vector	   for	   cloning	   the	   fusion	   FLAG+usual/novelMLL-­‐AF4	   cDNAs.	   The	  
contransfection	  of	   the	   tetO	  vector	  and	  another	  vector	   (Bs/IRES-­‐M2),	  encoding	   the	  reverse-­‐
tetracyclin	  transactivator	  (rtTA),	  allows	  the	  transcription	  of	  the	  cloned	  cDNA	  only	  when	  the	  
rtTA	   binds	   to	   the	   tetO	   cis-­‐element,	   in	   presence	   of	   doxycycline,	   an	   analogue	   of	   the	  
tetracycline.	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Following	  the	  manipulation	  procedures	  of	  the	  tetO/mEPO	  (kind	  gift	  from	  Prof.	  Pastore’s	  Lab,	  
Ceinge-­‐Biotecnologie	   Avanzate),	   aimed	   to	   excise	   the	   sequence	   encoding	   the	   murine	  
erythropoietin,	   the	  vector	   tetO	  and	  both	   the	  p3XFlag+usual/novelMLL-­‐AF4	   full	   length	  were	  
digested	  with	  SnaBI	  and	  BstXI	  endonucleases.	  Both	  vector	  and	  insert	  were	  loaded	  on	  0.8	  %	  
agarose	  gel	  and	  purified,	  as	  already	  described	  above.	  The	  ligation	  reaction	  was	  performed	  at	  
a	  molar	  concentration	  of	  2:1	  (vector	  :	  insert),	  by	  following	  the	  Ligafast	  Protocol	  (Promega).	  
Some	   colonies	  were	   tested	   by	   restriction	   digestion	   and	   sequenced	   at	   the	   Core	   Facility	   for	  
DNA	  Sequencing	  of	  Ceinge-­‐Biotecnologie	  Avanzate.	  	  
	  
Cell	  Cultures	  
Hek293	   and	   HeLa	   cells	   were	   cultured	   in	   Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM)	  
supplemented	  with	  10%	  Fetal	  Bovine	  Serum	  (FBS)	  and	  1%	  penicillin/streptomycin.	  
RS4;11	  is	  a	  cell	  line	  established	  from	  the	  bone	  marrow	  of	  a	  patient	  in	  relapse	  with	  an	  acute	  
leukemia	  that	  was	  characterized	  by	  the	  t(4;11)	  chromosomal	  abnormality	  (Stong	  et	  al,	  1985).	  
We	  used	  this	  cells	  to	  obtain	  the	  “usual”	  MLL-­‐AF4	  breakpoint.	  
697	   cell	   line	   is	   a	   cloned	   human	   pre-­‐B	   leukemic	   cell	   line	   derived	   from	   childhood	   acute	  
lymphoblastic	   leukemia	   that	   carries	   the	   t(1;19)	   translocation	   (Williams	   DL	   et	   al,	   1984;	  
Tsujimoto	  Y	  et	  al,	  1985).	  	  
Both	   RS4;11	   and	   697	   grow	   in	   suspension	   and	   were	   cultured	   in	   Roswell	   Park	   Memorial	  
Institute	  (RPMI)	  medium,	  with	  10%	  FBS.	  
All	  the	  cell	  cultures	  were	  incubated	  at	  37°C	  in	  humidified	  atmosphere	  with	  5	  %	  CO2.	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Enrichment	  and	  flow	  cytometric	  analysis	  of	  CD34+	  cells	  
Human	  hematopoietic	  stem	  and	  progenitor	  cells	  were	  collected	  from	  donors’	  cord	  blood	  of	  
the	  Biological	  Sample	  BioBank	  of	  Ceinge-­‐Biotecnologie	  Avanzate.	  CD34+	  cells	  were	  isolated	  in	  
high	   purity,	   by	   using	   MACS	   magnetic	   separation	   system	   (Miltenyi	   Biotech),	   according	   to	  
manifacturer’s	   instructions.	  Both	  positive	  and	  negative	  fractions	  were	  collected,	   in	  order	  to	  
analyze	   the	   purity	   degree	   of	   the	   eluted	   fractions	   by	   flow	   citometry.	   Cells	   from	   positive	  
elution,	  flow	  through	  and	  washes,	  respectively,	  were	  concentrated	  in	  100	  µl	  and	  stained	  with	  
the	   appropriate	   amount	   of	   anti-­‐CD34	   phycoeritrin	   (PE)-­‐conjugated	   (Becton	   Dickinson)	   and	  
anti-­‐CD45	  Peridinin	  Chlorophyll	  Protein	  (PerCP)-­‐conjugated	  (Becton	  Dickinson)	  for	  30’	  at	  4°C.	  
Then,	  the	  cells	  were	  washed	  and	  resuspended	  in	  200	  µl	  of	  PBS	  and	  analized	  with	  a	  FacsARIAII	  
cytometer	   of	   the	   Core	   Facility	   “Experimental	   and	   Clinical	   Flow	   Citometry”	   of	   Ceinge-­‐
Biotecnologie	  Avanzate.	  Cells	  gating	  and	  debris	  exclusion	  were	  performed	  by	  a	  FSC/SSC	  dot	  
plot;	  the	  frequency	  of	  CD34+	  cells	  was	  evaluated	  on	  a	  CD45-­‐PerCP	  versus	  CD34-­‐PE	  dot	  plot	  of	  
stained	  cells.	  The	  positive	  fraction	  was	  cultured	  in	  a	  24-­‐wells	  plate	  at	  a	  concentration	  of	  5	  X	  
105	   cells/well,	   in	   1	   ml	   of	   Iscove	   Modified	   Dulbecco’s	   Medium	   (IMDM)	   with	   1%	  
penicillin/streptomycin	  and	  10%	  FBS.	  
	  
Cell	  transfection	  
Hek293	  and	  HeLA	  cells	  were	   transfected	  with	  either	   Lipofectamine	   (Invitrogen)	  or	  Polyfect	  
(Qiagen),	  according	   to	   the	  manufacturers’	   instructions.	  For	   the	  tet-­‐on	  system,	  Hek293	  cells	  
were	  contransfected	  with	  the	  same	  amount	  of	  both	  plasmid	  tetO+usual/novelMLL-­‐AF4	  and	  
Bs/IRES-­‐M2	  and	  cultured	  with	  medium	  containing	  either	  0.1	  µl/ml	  or	  1	  µl/ml	  doxycycline.	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CD34+	  cells	  were	  transfected	  with	  Superfect	  (Qiagen)	  (Teixeira	  et	  al,	  2001).	  The	  transfection	  
efficiency	   was	   evaluated	   by	   Real-­‐Time	   PCR,	   detecting	   the	   MLL-­‐AF4	   transcript	   in	   both	  
transfected	  and	  mock	  control	  cells.	  
	  
Protein	  extraction,	  Western	  Blot	  and	  antibodies	  
48	   hours	   after	   the	   transfection,	   cells	  were	   spun	  down	   and	   resuspended	   in	   lysis	   buffer	   (50	  
mM	   pH	   8	   Tris-­‐HCl,	   150	   mM	   NaCl,	   0.1%	   NP-­‐40,	   1	   mM	   EDTA,	   10%	   Glycerol)	   with	   1:100	  
Protease	  Inhibitor	  Cocktail	  (Sigma)	  and	  0.5	  mM	  phenylmethylsulphonyl	  fluoride	  (PMSF)	  and	  
incubated	  on	   ice	   for	   20’.	   The	  whole	   cell	   extracts	   (WCE)	  were	   clarified	   by	   centrifugation	   at	  
12,000	   rpm	   for	   15’	   at	   4°	   C.	   The	   supernatants	  were	   collected	   and	   their	   concentration	  was	  
measured	  with	  the	  “Biorad	  Protein	  Assay”	  (BioRad).	  For	  the	  Western	  Blot	  analysis,	  either	  30	  
µg	  of	  WCE	  or	  20	  µl	  of	  immunocomplexes	  were	  denatured	  by	  heating	  in	  an	  equal	  volume	  of	  
Laemmli	   buffer	   (BioRad).	   The	   samples	   were	   loaded	   on	   Sodium	   Dodecyl	   Sulfate	   -­‐	  
Polyacrylamide	   Gel	   Electrophoresis	   (SDS-­‐PAGE),	   with	   a	   polyacrylamide	   mix	   percentage	  
spanning	   from	  8	   to	   12%,	   depending	   on	   the	  molecular	  weight	   of	   the	   protein	   of	   interest.	   A	  
molecular	  weight	  marker	  “Precision	  Plus	  ProteinTM	  Standards	  Dual	  Colors”	  (Biorad),	  as	  well,	  
was	   loaded	   on	   the	   gel,	   in	   order	   to	   test	   the	   precise	   molecular	   weight	   of	   the	   protein	   of	  
interest.	  The	  buffer	  used	  for	  the	  electrophoretic	  separation	  was	  Tris-­‐Glycine-­‐SDS.	  Then,	  the	  
proteins	  on	  the	  gel	  were	  transferred	  by	  elettroblotting	  to	  a	  PVDF	  membrane,	  which	  was	  first	  
incubated	   with	   Tween-­‐Tris-­‐Buffered-­‐Saline-­‐(TTBS)-­‐5%	  Milk	   for	   the	   blocking	   step,	   and	   then	  
probed	   with	   the	   following	   antibodies:	   anti-­‐FLAG	   (Sigma),	   anti-­‐CRSP33	   (Santa	   Cruz	  
Biotechnology,	   Inc),	   anti-­‐CRSP130	   (Santa	   Cruz	   Biotechnology,	   Inc),	   anti-­‐Cdk9	   (Santa	   Cruz	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Biotechnology,	   Inc),	   anti-­‐FGFR2	   (Santa	   Cruz	   Biotechnology,	   Inc),	   anti-­‐14-­‐3-­‐3	   θ	   (Santa	   Cruz	  
Biotechnology,	  Inc)	  and	  anti-­‐α	  tubulin	  (Sigma).	  The	  secondary	  antibodies	  were	  conjugated	  to	  
the	  HorseRadish	   Peroxidase	   (HRP)	   and	   the	   proteins	  were	   	   detected	   on	   the	   filter,	   by	   using	  
“ECL	  plus”	  kit	   (GE	  Healthcare)	   for	   the	   immunoprecipitates	  and	  “ECL”	  kit	   (GE	  Healthcare)	   in	  
the	  other	  cases.	  	  
	  
Semiquantitative-­‐PCR	  
For	   the	   Semiquantitative-­‐PCR	   analysis	   on	   HoxA9	   transcript,	   total	   RNA	  was	   extracted	   from	  
RS4;11,	   Hek293	   transfected	   with	   p3XFlag+usual/novelMLL-­‐AF4,	   control	   lymphocytes,	   and	  
mock	   control,	   respectively,	   by	   using	   the	   “RNAspin	  mini	   RNA	   isolation”	   kit	   (GE	  Healthcare),	  
which	  also	  provided	  the	  treatment	  with	  DNase,	  in	  order	  to	  degradate	  the	  DNA.	  5	  µg	  of	  each	  
RNA	  were	  retrotranscribed	  as	  already	  described	  above	  (see	  RT-­‐PCR	  in	  this	  section).	   	  3	  µl	  of	  
cDNA	  were	  used	  as	   template	   for	   the	   semiquantitative	  PCR.	   For	   this	   amplification	   reaction,	  
Taq	  DNA	  polymerase	  (Invitrogen)	  and	  1	  µl	  of	  HoxA9	  and	  GAPDH-­‐specific	  forward	  and	  reverse	  
primer	  (10	  µM)	  were	  added	  to	  the	  reaction	  mix.	  The	  reaction	  was	  carried	  out	  at	  32	  cycles,	  
then	   the	   PCR	   products	  were	   loaded	   on	   a	   1.5	  %	   agarose	   gel,	   containing	   ethidium	   bromide	  
(0.05	  µl/ml)	   in	  buffer	  4	  mM	  Tris-­‐Acetate-­‐EDTA	  (TAE).	  The	  bands	  were	  visualized	  at	  Gel	  Doc	  
with	   Quantity	   One	   (BioRad)	   software.	   The	   oligonucleotides	   used	   for	   the	   semiquantitative-­‐
PCR	   analysis	   of	   HoxA9	   and	   glyceraldehyde-­‐3	   phosphate-­‐dehydrogenase	   (GAPDH)	   are	  
contained	  in	  table	  1.	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RT-­‐Real	  Time	  PCR	  
The	   Real-­‐Time	   PCR	   was	   perfomed	   in	   triplicate	   for	   each	   sample.	   RNA	   was	   extracted	   as	  
described	   in	   the	   “Semiquantitative	   PCR”	   subparagraph	   and	   retrotranscribed	   with	  
“SuperScriptTM	   III	   Reverse	   Transcriptase”	   (Invitrogen)	   kit,	   with	   “Random	   Primers”	  
(Invitrogen).	  We	   used	   the	   iQTM	   SYBR	  Green	   Supermix	   (Bio-­‐Rad),	   in	  which	   dNTPs,	   Taq	  DNA	  
Polimerase,	  buffers	  MgCl2,	  and	  the	  intercalant	  probe	  SYBR	  GREEN	  are	  already	  premixed.	  For	  
each	  replicate,	  7.5	  µl	  of	  iQTM	  SYBR	  Green	  Supermix,	  1	  µl	  of	  each	  forward	  and	  reverse	  gene-­‐
specific	   primer	   (10	   µM)	   were	   mixed	   with	   sterile	   ddH2O,	   to	   a	   final	   volume	   of	   14	   µl.	   As	  
template	  of	  the	  reaction,	  either	  1	  µl	  of	  cDNA,	  retrotranscribed	  from	  1	  µg	  of	  RNA	  extracted	  
from	   Hek293	   or	   697	   cells,	   respectively,	   or	   2	  µl	   of	   cDNA,	   retrotranscribed	   from	   500	   ng	   of	  
CD34+	  cells-­‐derived	  RNA	  was	  used	  for	  each	  replicate.	  The	  Real-­‐Time	  protocol	  consisted	  in	  an	  
initial	  denaturation	  at	  95°C,	  followed	  by	  40	  cycles,	  each	  providing	  a	  step	  at	  95°C	  for	  15”	  and	  
another	   one	   at	   60°C	   for	   1’.	   The	   last	   cycle	   of	   the	   reaction	   consisted	   in	   a	   series	   of	   steps	   in	  
temperature	  gradient.	  From	  one	  step	  to	  the	  next	  one	  there	  was	  an	   increase	  of	  0.2°C,	  until	  
90°C.	  During	  this	  gradient	  the	  fluorescence	  emissed	  by	  the	  SYBR	  GREEN	  probe	  was	  detected	  
by	  the	  iCycler	  Real-­‐Time-­‐PCR	  software	  (BioRad),	  at	  a	  wavelength	  of	  490.	  The	  fold	  increase	  of	  
transcript	   expression	   was	   calculated	   with	   the	   formula:	   2-­‐ΔΔCt,	   where	   ΔCt	   is	   the	   difference	  
between	  the	  Ct	  of	  the	  gene	  of	   interest	  and	  the	  housekeeping	  gene	  in	  each	  cell	  population.	  
The	  primers	  used	  for	  the	  Real-­‐time	  PCR	  of	  HoxA9,	  FGFR2,	  β-­‐actin	  and	  β-­‐glucuronidase	  (GUS)	  
are	  contained	  in	  table	  1.	  
	  
	  





















HOXA9	  F	   TGTGGTTCTCCTCCAGTTGATAGAG	  
	  
HOXA9	  R	   TCGGTGAGGTTGAGCAGTCGAG	  
GAPDH	  F	   GGTCGTATTGGGCGCCTGGTCA	  
	  
GAPDH	  R	   CCAACCCATGACGAACATGGGGGC	  
β-­‐ACTIN	  F	   CGCGACAGGATGCAGAAGGAGA	  
β-­‐ACTIN	  R	   CGTCATACTCCTGCTTGCTG	  
FGFR2	  F	   CTCAAGCACTCGGGGATAAA	  
FGFR2	  R	   TGTTTTGGCAGGACAGTGAG	  
GUS	  F	   GAAAATATGTGGTTGGAGAGCTCATT	  
GUS	  R	   CCGAGTGAAGATCCCCTTTTTA	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Immunofluorescence	  
2	  X	  104	  HeLa	  cells	  were	  seeded	  in	  a	  chamber-­‐slide	  (Nalgene-­‐Nunc)	  and	  cultured	  in	  300	  µl	  of	  
fresh	   medium	   at	   37°C.	   After	   24	   h,	   the	   cells	   were	   transfected	   (Polyfect,	   Qiagen)	   with	   the	  
recombinant	  constructs	  and	  cultured	  for	  48	  hours	  at	  37°C.	  Then,	  the	  cells	  were	  fixed	  in	  4%	  
PBS	  paraformaldheyde	  solution	  for	  5’	  at	  room	  temperature	  (RT)	  and	  permeabilized	  with	  0.2	  
%	  Triton	  in	  PBS	  for	  30’	  at	  RT.	  After	  the	  permeabilization,	  the	  cells	  were	  first	  incubated	  for	  1	  h	  
at	  RT	  with	  2%	  Bovine	  Serum	  Albumin	  (BSA),	  10	  %	  FBS,	  0.1	  %	  Triton	   in	  PBS	  for	  the	  blocking	  
and	   then	   with	   the	   primary	   antibody	   solution:	   2%	   BSA,	   10	   %	   FBS,	   0.1	   %	   Triton	   in	   PBS,	  
containing	  a	  dilution	  of	  1:500	  α-­‐Flag,	   for	  3	  h	  at	  RT.	  Then,	  a	   second	   incubation	   in	  dark	  was	  
performed	   with	   the	   same	   solution,	   containing	   the	   fluoresceine	   isotyocyanate	   (FITC)-­‐
conjugated	  α-­‐mouse	  in	  a	  1:100	  dilution.	  Between	  each	  step,	  cells	  were	  washed	  with	  PBS	  to	  
discard	  the	  reagents	  in	  excess.	  
After	   the	   last	  wash,	   each	  well	  was	   incubated	   for	   5’	   at	   RT	  with	   200	  µl	   of	   4’,6-­‐diamidino-­‐2-­‐
phenylindole	  (DAPI)	  solution	  (0.05	  µg/mL	  in	  PBS).	  The	  chamber-­‐slide	  was	  then	  left	  to	  air	  dry	  
and	  analized	  at	  a	  fluorescence	  microscope	  (Zeiss).	  The	  digital	  images	  were	  taken	  by	  an	  Axio	  
Vision	  (Zeiss)	  software.	  
	  
Immunoprecipitation	  Assay	  
The	   total	   proteins	   extracted	   from	   the	   transfected	   cells	   were	   immunoprecipitated,	   by	  
incubation	   with	   anti-­‐Flag	   agarose	  microbeads	   (Anti-­‐FLAG	  M2	   affinity	   gel,	   Sigma).	   40	  µl	   of	  
microbeads	  were	  used	  for	  every	  10	  mg	  of	  WCE.	  Before	  starting	  the	  immunoprecipitation,	  the	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microbeads	  were	  spun	  down	  and	  the	  supernatant	  discarded.	  The	  beads	  were	  first	  washed	  3	  
times	  with	   a	   buffer	   containing	   50	  mM	   Tris,	   150	  mM	  pH8	  NaCl,	   1mM	  pH8	   EDTA	   and	   then	  
incubated	  with	  the	  appropriate	  amount	  of	  WCE	  for	  3	  h	  at	  4°C	  on	  a	  wheeling	  device.	  Then,	  
the	  microbeads	  were	  spun	  down	  at	  3,000	  rpm	  for	  5’	  and	  washed	  3	  times	  with	  with	  a	  buffer	  
containing	  50	  mM	  Tris,	  300	  mM	  pH	  8	  NaCl,	  10%	  Glycerol,	  0.5	  PMSF,	  1mM	  EDTA,	  0.1	  %	  NP-­‐40,	  
1:	   100	   Protease	   inhibitor	   Cocktail	   (PIC).	   Then,	   the	  microbeads	  were	  washed	   3	  more	   times	  
with	  50	  mM	  Tris,	  150	  mM	  pH	  8	  NaCl,	  10%	  Glycerol,	  0.5	  mM	  PMSF,	  1	  mM	  EDTA,	  0.1	  %	  NP-­‐40,	  
1:100	  PIC	  and,	   then,	   transferred	  on	  a	  microcolumn.	  The	   last	  wash	  buffer	  was	  discarded	  by	  
spinning	   the	   column.	   The	   elution	   of	   the	   proteins	   from	   the	  microbeads	  was	   carried	   out	   by	  
incubating	  the	  column	  for	  15’	  at	  4	  °C	  with	  buffer	  containing	  50	  mM	  TRIS,	  150	  mM	  pH	  8	  NaCl,	  
10%	  Glycerol,	  0.5mM	  PMSF,	  1mM	  EDTA,	  0,1%	  NP-­‐40,	  1:100	  PIC,	  and	  200	  μg/ml	  peptide	  FLAG	  
(Sigma).	  The	  eluted	  protein	  fraction	  was	  collected,	  by	  centrifugation	  at	  3,000	  rpm	  for	  2’	  and	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Results	  
3.1	  Cloning	  of	  cDNA	  encoding	  MLL-­‐AF4	  in	  the	  p3XFLAG	  vector	  
Most	   of	   the	   AF4	   molecular	   partners	   that	   were	   identified	   in	   our	   group	   by	   the	  
proteomics	  experiments	  are	   involved	   in	   the	  regulation	  of	   the	  Pol	   II-­‐mediated	  transcription,	  
thus	   suggesting	   a	   direct	   role	   of	   AF4	   in	   this	   process.	  Here,	  we	   asked	  whether	   the	  MLL-­‐AF4	  
fusion	  shares	  one	  or	  more	  partners	  with	   the	  native	  AF4,	  and	  how	  these	   interactions	  could	  
influence	  and	  regulate	  the	  aberrant	  activity	  of	  the	  MLL-­‐AF4	  chimaera.	  Thus,	  the	  first	  aim	  of	  
the	   present	   project	   was	   to	   create	   a	   cell	   system	   that	   exogenously	   expressed	   the	  MLL-­‐AF4	  
chimaeric	  protein.	  	  
We	  cloned	  the	  cDNA	  of	  the	  MLL-­‐AF4	  fusion	  protein	  to	  characterize	  their	   interaction	  
with	  other	  members	  of	  the	  complex	  in	  which	  the	  native	  AF4	  protein	  is	  involved.	  
To	  clone	  the	  cDNA	  encoding	  MLL-­‐AF4	  fusion	  protein,	  we	  chose	  two	  different	  variants	  
of	  MLL-­‐AF4:	   the	  most	  common	  one	   found	   in	  ALL	  patients	  carrying	   t(4;11),	  which	  we	  called	  
“usualMLL-­‐AF4”	  and	  a	  more	  rare	  and	  smaller	  one,	  detected	  by	  our	  group	  (Pane	  et	  al,	  2002)	  in	  
an	   infant	   ALL	   patient,	   that	   we	   called	   “novelMLL-­‐AF4”.	   The	   reason	   why	   we	   cloned	   both	  
isoforms	  was	  that	  the	  novel	  breakpoint	  had	  a	  smaller	  AF4	  portion	  and	  we	  could	  eventually	  
expect	  differences	  in	  the	  interactome	  of	  the	  two	  different	  isoforms.	  	  
We	   cloned	   the	  usual	   isoform	   by	   reverse	   transcription	   of	   the	   RNA	   from	   RS4;11	   cell	  
line.	  The	  MLL-­‐AF4	  breakpoint	  carried	  by	  these	  cells	  is	  an	  in-­‐frame	  fusion	  between	  the	  exon	  9	  
of	  MLL	  and	  the	  exon	  4	  of	  AF4.	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Because	  of	  the	  wide	  length	  of	  this	  fusion	  cDNA	  (6.681	  kb),	  we	  decided	  to	  amplify	  the	  
cDNA	  in	  3	  three	  different	  overlapping	  fragments,	  by	  using	  primer	  pairs,	  each	  specific	  for	  the	  
following	   fragments:	   “MAF1-­‐2-­‐3”,	   “usualMLL-­‐AF4	   breakpoint”	   and	   “AF4”	   (fig	   7).	   Then,	   we	  
subcloned	   all	   the	   three	   PCR	   products	   in	   the	   entry	   vector	   pCRIITOPO.	   We	   chose	   the	  
p3XFLAG7.1	  as	  final	  destination	  vector	  because	  it	  usually	  allows	  high	  levels	  of	  transcription	  of	  
cloned	  genes,	   thanks	   to	   the	  upstream	  strong	  eukaryotic	  CMV	   (Cytomegalovirus)	  promoter.	  
Furthermore,	  this	  plasmid	  allows	  an	  N-­‐terminal	  in-­‐frame	  fusion	  of	  the	  cDNA	  of	  MLL-­‐AF4	  with	  
a	   sequence	   (triple	   epitope	   FLAG),	   which	   is	   easily	   recognized	   by	   a	   specific	   monoclonal	  
antibody	   (anti-­‐FLAG),	   thereby	   facilitating	   the	   detection	   and/or	   purification	   of	   the	  
recombinant	  proteins.	  	  
We	   engineered	   the	   novel	   construct	   by	   specific	   amplification	   of	   the	   regions	  
immediately	   upstream	   and	   downstream	   of	   the	   sequences	   lacking	   in	   the	   novel	   fusion	  
breakpoint,	   followed	   by	   a	   ligation	   reaction	   (see	   fig.	   6	   in	   the	  Materials&Methods	   section).	  
Fragments	  “MAF1-­‐2-­‐3”	  and	  “usual/novelMLL-­‐AF4breakpoint”	  were	  respectively	  cloned	  in	  the	  
p3XFLAG	  (Fig.	  8).	  Then,	  we	  digested	  the	  subclone	  “usualMLL-­‐AF4	  breakpoint”	  by	  restriction	  
enzyme	   and	   inserted	   it	   into	   the	   p3XFLAG+AF4	   construct	   (fig.	   9A).	   Lastly,	   we	   inserted	   the	  
fragment	   “MAF1-­‐2-­‐3”	   from	   p3XFLAG+MAF1-­‐2-­‐3,	   upstream	   to	   the	   sequence	   “usualMLL-­‐















Fig.	  7.	  Subdivision	  of	  MLL-­‐AF4	  cDNA	  in	  3	  overlapping	  fragments.	  The	  first	  fragment	  “MAF1-­‐
2-­‐3”	   includes	   the	   sequence	   encoding	   all	   the	   MLL	   N-­‐terminal	   domains;	   the	   “MLL-­‐AF4”	  
breakpoint	   is	   the	  sequence	  corresponding	  to	  the	  “usual”	   junction	  region	  between	  MLL	  and	  
AF4;	  the	  third	  fragment,	  “AF4”,	  encodes	  all	  the	  C-­‐terminal	  domains	  of	  the	  AF4	  protein.	  
	  
	  
Fig.	  8.	  Cloning	  of	  the	  4	  cDNA	  fragments	  covering	  the	  whole	  MLL-­‐AF4	  sequence.	  The	  single	  
fragments,	  “MAF1-­‐2-­‐3”,	  “usualMLL-­‐AF4	  breakpoint”,	  “novelMLL-­‐AF4	  breakpoint”	  and	  “AF4”,	  
each	   containing	   its	   own	   open	   reading	   frame,	   has	   been	   cloned	   in	   the	   p3Xflag	   eukaryotic	  
expression	  vector.	  













Fig.	   9.	   Cloning	   procedure	   of	   the	   full	   length	   MLL-­‐AF4.	   Both	   usual	   and	   novel	   MLL-­‐AF4	  
breakpoint	  have	  been	  excised	   from	   the	  original	   p3XFlag	   constructs	  by	   restriction	  digestion	  
and	   cloned	   in	   the	   p3XFlag+AF4,	   digested	  by	   the	   same	  enzymes	   (A).	   Then,	   the	   “MAF1-­‐2-­‐3”	  
portion	  was	  added	  upstream	  to	  the	  usual/novelMLL-­‐AF4	  constructs,	  thus	  obtaining	  both	  the	  
usual	  and	  the	  novel	  MLL-­‐AF4	  full	  length	  (B).	  
B	  
A	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Positive	   clones	   were	   selected	   by	   RE	   digestion.	   Correct	   size	   of	   DNA	   bands	   was	  
detected	  by	  gel	  electrophoresis.	  Integrity	  of	  one	  positive	  clone	  was	  verified	  by	  sequencing.	  
	  
3.2	  Expression	  of	  recombinant	  MLL-­‐AF4	  in	  human	  cell	  lines	  
We	   transiently	   transfected	   HEK293	   and	   HeLa	   cells	   with	   the	   plasmids	  
p3XFLAG+usualMLL-­‐AF4,	   p3XFLAG+novelMLL-­‐AF4,	   p3XFLAG+MAF1-­‐2-­‐3,	   p3XFLAG+usualMLL-­‐
AF4	   full	   length	  and	  p3XFLAG+novelMLL-­‐AF4	   full	   length	   (fig.	   10),	  by	   liposome	  methodology.	  
After	  48	  hours,	  we	  extracted	  total	  proteins	  from	  both	  transfected	  and	  non-­‐transfected	  cells	  
and	  detected	  the	  fusion	  protein	  by	  using	  recombinant	  specific	  anti-­‐FLAG	  antibody	  in	  Western	  
blot	  experiment.	  As	  shown	  in	  fig.	  11,	  Western	  Blot	  revealed	  an	  efficient	  expression	  of	  all	  the	  
recombinant	   proteins:	   usualMLL-­‐AF4	   breakpoint	   (110	   kDa),	   novelMLL-­‐AF4	   breakpoint	   (90	  
kDa),	  usualMLL-­‐AF4	  full	  length	  (230	  KDa),	  novelMLL-­‐AF4	  full	  length	  (210	  KDa),	  MAF1-­‐2-­‐3	  (128	  


















Fig	   10.	   Schematic	   representation	   of	   the	   FLAG-­‐protein	   constructs	   obtained.	   All	   the	   five	  
constructs	  cloned	   in	   the	  p3XFlag	  had	   their	  own	  ORF,	   in-­‐frame	  with	   the	  sequence	  encoding	  
the	  upstream	  triple	  epitope	  FLAG.	  Each	  one	  of	  these	  five	  cDNA	  produced	  a	  different	  protein,	  
fused	  with	  the	  triple-­‐epitope	  FLAG	  at	  the	  N-­‐terminus.	  	  
	  
	  






Fig	   11.	   Transient	   expression	   analysis	   of	   the	   FLAG-­‐recombinant	   proteins.	   50	  µg	   of	   whole	  
protein	   extracts	   from	   HEK293	   cells	   transfected	   respectively	   with	   empty	   p3XFLAG	   vector,	  
FLAG-­‐usualMLL-­‐AF4	   breakpoint,	   FLAG-­‐novelMLL-­‐AF4	   breakpoint,	   FLAG-­‐usualMLL-­‐AF4	   full	  
length,	  FLAG-­‐novelMLL-­‐AF4	  full	  length,	  FLAG-­‐MAF1-­‐2-­‐3,	  were	  resolved	  on	  8%	  SDS-­‐PAGE	  and	  
analyzed	   by	   western	   blot.	   The	   α-­‐Flag	   antibody,	   used	   at	   a	   dilution	   of	   1:5000,	   recognized	  
specific	  bands	  at	  the	  expected	  molecular	  weight:	  FLAG-­‐usualMLL-­‐AF4	  breakpoint	  (110	  kDa),	  
FLAG-­‐novelMLL-­‐AF4	  breakpoint	  (90	  kDa),	  FLAG-­‐usualMLL-­‐AF4	  full	  length	  (230	  kDa)	  and	  FLAG-­‐
novelMLL-­‐AF4	  full	  length	  (210	  KDa),	  FLAG-­‐MAF1-­‐2-­‐3	  (128	  KDa).	  No	  band	  was	  detected	  in	  the	  
mock	   control	   lane.	   The	   membrane	   was	   also	   probed	   with	   α-­‐tubulin	   (55	   kDa)	   as	   loading	  
control.	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3.3	  Inducible	  expression	  system	  of	  MLL-­‐AF4	  chimaeras	  
	   In	   order	   to	   obtain	   an	   inducible	   expression	   system	   of	   MLL-­‐AF4	   chimeric	   protein,	  
detectable	   by	   α-­‐flag	   antibody,	   we	   cloned	   cDNA	   encoding	   FLAG-­‐usual/novelMLL-­‐AF4	   full	  
length	  in	  the	  TetO-­‐mEPO	  vector,	  which	  we	  manipulated	  to	  remove	  the	  insert,	  e.g.	  the	  cDNA	  
encoding	   the	  murine	  erythropoietin	   (mEPO),	   and	   replace	   this	   sequence	  with	   the	   cDNAs	  of	  
our	   interest	   (Fig.	   12).	   Then	   we	   cotransfected	   Hek293	   cells	   with	   tetO+usual/novelMLL-­‐AF4	  
and	   the	   BS/IRES-­‐M2	   vector,	   containing	   the	   sequence	   encoding	   the	   reverse	   tetracycline	  
transactivator	  2S-­‐M2	  (rtTA2S-­‐M2).	  In	  presence	  of	  doxycycline,	  this	  chimaerical	  transcriptional	  
factor	  specifically	  binds	  the	  target	  promoter	  (tetO)	  (Koponen	  et	  al,	  2003;	  Salucci	  et	  al,	  2002),	  
and	  activates	  the	  transcription	  of	  the	  downstream	  cDNA.	  	  
We	   tested	   the	   expression	   of	   FLAG-­‐chimaeras	   in	   the	   cotransfected	   Hek293	   cells,	  
cultured	  in	  medium	  either	  with	  or	  without	  doxycyclin,	  by	  Western	  Blot	  analysis.	  As	  shown	  in	  
the	  fig.13,	  we	  had	  the	  expression	  of	  recombinant	  proteins	  only	  after	  adding	  doxycyclin	  into	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Fig.	   12.	   Cloning	   of	   the	   cDNAs	   encoding	   FLAG-­‐usual/novelMLL-­‐AF4	   full	   length	   in	   a	   tet-­‐on	  
vector.	  Following	  the	  removal	  of	  the	   insert	  cDNA	  encoding	  the	  murine	  erythropoietin	  from	  
the	   tetO/mEPO	  vector,	   the	   cDNAs	  encoding	   the	   FLAG-­‐usual/novelMLL-­‐AF4	   full	   length	  have	  
been	  excised	  from	  the	  p3XFLAG	  constructs	  and	  insert	  in	  the	  Multiple	  Cloning	  Site	  of	  the	  tetO	  
vector.	   This	   plasmid	   contains	   a	   tetO	   cis-­‐element	   fused	   to	   a	   CMV	  minimal	   promoter,	   thus	  
allowing	  the	  regulated	  expression	  of	  the	  cDNA	  of	  interest,	  in	  presence	  of	  doxycyclin	  and	  the	  
reverse-­‐tetracycline	  transactivator.	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Fig.	   13.	   Analysis	   of	   FLAG-­‐recombinant	   proteins	   expression	   in	   a	   system	   inducible	   by	  
doxycycline.	   50	   µg	   of	   whole	   protein	   extracts	   from	   HEK293	   cells	   cotransfected	   in	   either	  
absence	  or	  presence	  of	  doxycycline	  in	  the	  medium,	  with	  either	  tetO+FLAG-­‐usualMLL-­‐AF4	  full	  
length	   or	   tetO+FLAG-­‐novelMLL-­‐AF4	   full	   length	   plasmids,	   respectively,	   and	   the	   Bs/IRES-­‐M2	  
vector,	  were	  loaded	  and	  resolved	  on	  8%	  SDS-­‐PAGE	  and	  analyzed	  by	  western	  blot.	  The	  α-­‐Flag	  
antibody	  (1:5000	  diluted)	  recognized	  specific	  bands	  at	  the	  molecular	  weight	  of	  210/230	  KDa	  
for	  both	  FLAG-­‐usualMLL-­‐AF4	  full	  length	  and	  FLAG-­‐novelMLL-­‐AF4	  full	  length	  only	  in	  the	  lanes	  
corresponding	   to	   the	  cells	   treated	  with	  either	  0.1	  or	  1	  µg/mL	  of	  doxycyclin.	  No	  FLAG-­‐MLL-­‐
AF4	   protein	   is	   detectable	   in	   the	   untreated	   cells,	   because	   of	   the	   expression	   of	   the	   tTS	  
repressor,	  which	  is	  encoded	  by	  the	  Bs/IRES-­‐M2	  vector	  and,	  in	  absence	  of	  doxycycline,	  binds	  
to	  tetO,	  blocking	  the	  basal	  expression	  of	  the	  cloned	  cDNAs.	  The	  membrane	  was	  also	  probed	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3.4	  The	  recombinant	  FLAG-­‐MLL-­‐AF4	  chimaeras	  localize	  into	  the	  nucleus	  
Although	  our	  doxycycline-­‐inducible	  system	  allowed	  us	   to	  have	  a	  suitable	  expression	  
level	  of	  the	  MLL-­‐AF4	  chimaeras,	  we	  used	  the	  non-­‐regulated	  expression	  system	  with	  p3XFlag	  
for	  the	  following	  experiments.	  
We	   first	   investigated	   the	   subcellular	   localization	   of	   our	   recombinant	   proteins,	   by	  
immunofluorescence.	  We	   transiently	   transfected	  HeLa	   and	  Hek293	   cells	   and	   stained	   them	  
with	   the	   anti-­‐FLAG	   primary	   antibody	   and	   then	   with	   fluorochrome	   (FITC)-­‐conjugated	  
secondary	  antibody.	  The	  fixed	  cells	  were	  also	  stained	  with	  DAPI,	  in	  order	  to	  detect	  the	  nuclei	  
of	   the	   cells.	   In	   the	   merged	   section,	   the	   FITC	   signals,	   corresponding	   to	   the	   recombinant	  
proteins,	   colocalized	   with	   DAPI,	   thereby	   indicating	   that	   both	   chimaeras	   migrate	   into	   the	  
nucleus,	   as	   expected	  because	  of	   the	  Nuclear	   Localization/Targeting	   Sequence	  of	   both	  MLL	  
and	  AF4	  proteins	  (NLS).	  
Interestingly,	   we	   observed	   that,	   although	   the	   “usual/novelMLL-­‐AF4	   breakpoint”	  
constructs	   lacked	  the	  Nuclear	  Localization	  Signal	  of	  MLL,	   they	  could	  still	   reach	  the	  nucleus,	  
suggesting	  that	  the	  NLS	  of	  AF4	  are	  sufficient	  to	  allow	  the	  transport	  of	  the	  MLL-­‐AF4	  proteins	  





	   51	  
Fig.	   14.	   The	  FLAG-­‐usual/novelMLL-­‐AF4	   chimaeras	   localize	   into	   the	  nucleus.	  HeLa	   cells	  were	  
transfected	   with	   “p3XFLAG+usualMLL-­‐AF4	   full	   length”	   (A),	   “p3XFLAG+novelMLL-­‐AF4	   full	  
length”	   (B)	   and	   “p3XFLAG+MAF1-­‐2-­‐3”	   (C),	   “p3XFLAG+usualMLL-­‐AF4	   breakpoint”	   (D)	   and	  
“p3XFLAG+novelMLL-­‐AF4	  breakpoint”	  (E).	  Cells	  were	  stained	  with	  FITC	  and	  DAPI	  and	  analyzed	  
by	   immunofluorescence	  microscopy.	   The	   DAPI	   channel	   shows	   the	   nuclear	   staining,	  whereas	  
the	  FITC	  channel	  detects	  the	  signal	  of	  the	  specific	  FLAG-­‐MLL-­‐AF4	  construct.	  The	  left	  lane	  is	  the	  
merged	  image	  of	  DAPI	  and	  FITC.	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3.5	  The	  recombinant	  FLAG-­‐MLL-­‐AF4	  proteins	  up-­‐regulate	  the	  HoxA9	  gene	  
The	  MLL	   gene	   positively	   regulates	   the	   homeobox	   gene	   HoxA9	   and	   the	   homeobox	  
cofactor	   Meis1	   (Milne	   et	   al,	   2002).	   Furthermore,	   Meis1	   and	   HoxA9	   are	   among	   the	   most	  
common	  targets	  of	  MLL-­‐AF4	  chimaera	  by	  ChIP-­‐seq	  (Guenther	  et	  al,	  2008).	  
Therefore,	  we	   investigated	  the	  expression	   level	  of	  HoxA9	  gene	  by	  semi-­‐quantitative	  
PCR.	  Below	  is	  a	  list	  of	  the	  cell	  lines	  we	  used:	  
• RS4;11,	   the	   ALL	   lymphoblastoid	   cell	   line	   that	   endogenously	   express	   the	  usual	  MLL-­‐
AF4	  protein;	  
• HEK293	  cells,	  transfected	  respectively	  with	  p3XFLAG+MAF1-­‐2-­‐3,	  “usualMLL-­‐AF4”	  and	  
“novelMLL-­‐AF4”;	  	  
• Immortalized	  lymphocytes,	  as	  a	  control	  for	  the	  basal	  expression	  of	  HoxA9	  gene	  in	  the	  
blood	  cells;	  
• non-­‐transfected	  HEK293	  cells,	  as	  a	  negative	  control	  (MOCK).	  
We	  extracted	  total	  RNA	  from	  these	  cells	  and	  reverse	  transcribed	  it	  into	  cDNAs.	  Then,	  
we	   amplified	   the	   cDNA	   by	   PCR	   using	   HoxA9-­‐	   and	   GAPDH	   (glycerladeyde-­‐phosphate	  
dehydrogenase)-­‐specific	   primers.	   As	   shown	   in	   fig.	   15,	   the	   amplification	   product	   is	   a	   clear	  
band	   at	   the	   expected	   molecular	   size	   in	   the	   RS4;11,	   in	   the	   Hek293	   cells	   expressing	   both	  
usual/novel	  MLL-­‐AF4,	  thus	  demonstrating	  that	  our	  recombinant	  chimaeras	  were	  able	  to	  up-­‐
regulate	  the	  HoxA9	  gene.	  	  
Notably,	  HOXA9	   expression	  was	   also	  detected	   in	  Hek293	  overexpressing	  MAF1-­‐2-­‐3.	  
This	  data	  confirmed	  the	  findings	  from	  Martin	  et	  al	  (2003),	  showing	  that	  also	  truncated	  forms	  
of	  MLL	  are	  sufficient	  to	  work	  as	  potent	  transcriptional	  activators.	  













Fig	  15.	  Recombinant	  FLAG-­‐MLL-­‐AF4	  induces	  the	  expression	  of	  HOXA9.	  cDNAs	  derived	  from	  
RS4;11	   cells,	   HEK293	   cells	   transfected	   with	   p3XFlag+MAF1-­‐2-­‐3,	   p3XFlag+usualMLL-­‐AF4	   full	  
length,	   p3XFlag+novelMLL-­‐AF4	   full	   length,	   empty	   p3XFlag,	   respectively,	   and	   control	  
lymphocytes	  were	  amplified	  in	  semi-­‐quantitative	  conditions	  with	  oligonucleotides	  specific	  for	  
the	  HoxA9	  transcript.	  The	  PCR	  products	  were	   loaded	  on	  0.8%	  agarose	  gel	  and	  visualized	  at	  
the	   UV	   GelDoc	   (BioRad).	   A	   specific	   band	   at	   270	   bp	   is	   visible	   in	   the	   RS4;11,	   MAF1-­‐2-­‐3,	  
usualMLL-­‐AF4	  and	  novelMLL-­‐AF4	  lanes,	  thus	  indicating	  the	  expression	  of	  HoxA9	  induced	  by	  
the	  chimaera	  full	  length	  and	  the	  N-­‐terminal	  portion	  in	  the	  endogenous	  system	  of	  RS4;11	  cells	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3.6	   MLL-­‐AF4	   interacts	   with	   Cyclin-­‐dependent-­‐Kinase	   9	   (CdK9)	   and	   with	  
members	  of	  the	  “Mediator	  Complex”	  
Bitoun	   et	   al	   (2007)	   showed	   that	   AF4	   associates	   with	   the	   Positive-­‐Transcription	  
elongation	   Factor	   b	   (P-­‐TEFb),	   a	   dimeric	   complex	   formed	   by	   Cyclin	   T1	   and	   CdK9,	   which	   is	  
involved	  in	  the	  activation	  of	  the	  RNA-­‐pol	  II-­‐mediated	  transcription.	  They	  demonstrated	  that	  
AF4	  coimmunoprecipitates	  with	  Cyclin	  T1	  and	  CdK9	  and	  that	  AF4	  is	  a	  positive	  regulator	  of	  P-­‐
TEFb	  kinase	  activity	  and	  elongation	  function.	  Therefore,	  AF4	  is	  a	  positive	  regulator	  of	  the	  Pol	  
II	  transcriptional	  elongation.	  
Here,	   we	   evaluated	   the	   possible	   interaction	   between	   MLL-­‐AF4	   and	   CdK9.	   We	  
transfected	   HEK293	   cells	   with	   p3XFLAG+usual/novelMLL-­‐AF4	   and	   extracted	   total	   proteins.	  
Then	  we	   immunoprecipitated	  the	  FLAG-­‐usual/novelMLL-­‐AF4	  recombinant	  proteins	  by	  using	  
anti-­‐FLAG	   agarose	   beads	   and	   analyzed	   the	   immunocomplexes	   by	  Western	   Blot	   with	   anti-­‐
CdK9	   antibody	   (Fig.16).	   As	   shown	   in	   Fig	   16,	   both	  MLL-­‐AF4	   chimaeras	   interact	   with	   CdK9,	  
whereas	   the	   MAF1-­‐2-­‐3	   does	   not,	   thus	   confirming	   that	   the	   portion	   of	   AF4	   present	   in	   the	  
chimaera	   is	   involved	   in	   this	   binding.	  We	   also	   detected	   the	   CdK9	   protein	   in	   the	  whole	   cell	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Fig	  16.	  Western	  blot	  analysis	  reveals	  the	  interaction	  of	  both	  usual	  and	  novel	  MLL-­‐AF4	  with	  
CdK9.	  48	  hours	  after	  the	  transfection	  of	  the	  HEK293	  cells	  with	  the	  usualMLL-­‐AF4	  full	  length,	  
novelMLL-­‐AF4	   full	   length,	  MAF1-­‐2-­‐3	   and	   empty	   vector	   (mock),	   respectively,	   the	  whole	   cell	  
proteins	   were	   collected.	   10	   mg	   of	   whole	   cell	   extracts	   (WCE)	   were	   used	   as	   input	   for	   the	  
immunoprecipitation	   assay,	   by	   using	   agarose	   anti-­‐FLAG	   beads.	   20	   µl	   of	   the	  
immunocomplexes	   and	   50	   µg	   of	   WCEs	   were	   loaded	   and	   resolved	   on	   12%	   SDS-­‐PAGE	   and	  
analyzed	  by	  western	  blot.	  The	  α-­‐CdK9	  antibody,	  used	  at	  a	  dilution	  of	  1:1000,	   recognized	  a	  
specific	   band	   at	   43	   kDa	   in	   immunoprecipitates	   (IP)	   of	   both	   usual	   and	   novel	   MLL-­‐AF4-­‐
expressing	  cells,	  but	  not	   in	   the	  MAF1-­‐2-­‐3	  and	  mock	  corresponding	   lanes.	  The	  43	  kDa	  band	  
was	  also	  detected	  in	  all	  the	  WCEs	  used	  as	  input	  of	  the	  immunoprecipitation	  assays.	  	  
	  
A	   recent	   study	   from	  our	   group	  of	   the	   interactome	  of	   the	  AF4	  protein	   showed	   that	  
some	  of	  the	  AF4	  interactors	  belong	  to	  the	  so-­‐called	  “Mediator	  Complex”,	  which	  is	  involved	  in	  
the	   regulation	   of	   the	   Pol	   II-­‐mediated	   transcription.	   Since	   the	   MLL-­‐AF4	   chimeric	   protein	  
includes	   the	   C-­‐terminus	   and	   the	   transactivaction	   domain	   of	   AF4,	   we	   also	   tested	   some	  
Mediator’s	  members	  as	  partners	  of	  MLL-­‐AF4,	  too.	  To	  this	  aim,	  we	  expressed	  the	  flagged	  MLL-­‐
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AF4	  proteins	   in	  HEK293	   cells	   and	   immunoprecipitated	   the	  protein	   complexes	  by	   anti-­‐FLAG	  
agarose	  beads.	  The	  immunocomplexes	  were	  resolved	  by	  SDS-­‐PAGE	  and	  analyzed	  by	  Western	  
Blot,	  using	  anti-­‐CRSP33	  and	  CRSP130	  antibodies.	  The	  Western	  Blot	  results	  showed	  that	  while	  
both	   chimaeras	   interact	   with	   CRSP130	   (Fig.	   17A),	   only	   the	   “usual”	   chimera	   interacts	   with	  
CRSP33	  (Fig.	  17B).	  This	  suggests	  that	  the	  binding	  domain	  of	  AF4	  and	  MLL-­‐AF4	  to	  CRSP33	   is	  
localized	  in	  the	  portion	  of	  the	  AF4	  that	  is	  lost	  in	  the	  novel	  isoform.	  











Fig	  17.	  MLL-­‐AF4	  interacts	  with	  CRSP130	  and	  CRSP33,	  members	  of	  the	  “Mediator	  Complex”.	  
The	   immunoprecipitation	   assays	   were	   performed	   as	   already	   reported	   above.	   20	   µl	   of	  
immunocomplexes	   and	   50	   µg	   of	   WCEs	   were	   loaded	   and	   resolved	   on	   10%	   SDS-­‐PAGE	   and	  
analyzed	  by	  western	  blot.	  The	  α-­‐CRSP130	  antibody	  detected	  specific	  band	  at	  130	  in	  the	  IP	  of	  
both	   usual	   and	   novel	  MLL-­‐AF4-­‐expressing	   cells,	   whereas	   the	  α-­‐CRSP33	   revealed	   a	   specific	  
band	  at	  33	  kDa	  only	  in	  the	  IP	  from	  the	  cells	  that	  express	  the	  usual	  chimaera.	  Both	  33	  kDa	  and	  
130	  kDa	  bands	  were	  also	  detected	  in	  all	  the	  WCEs	  of	  transfected	  cells,	  used	  as	  input	  of	  the	  
immunoprecipitation	   assays,	   but	   no	   band	   was	   detected	   in	   the	   IP	   of	   FLAG-­‐MAF1-­‐2-­‐3	  
transfected	   cells	   and	   in	   the	   mock	   transfection	   control.	   Both	   α-­‐CRSP-­‐130	   and	   α-­‐CRSP-­‐33	  
primary	  antibodies	  were	  used	  at	  a	  dilution	  of	  1:200.	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3.7	  14-­‐3-­‐3	  θ 	  binds	  MLL-­‐AF4	  and	  this	  interaction	  affects	  the	  expression	  of	  MLL	  
target	  gene	  
The	   14-­‐3-­‐3s	   belong	   to	   a	   family	   of	   proteins	   that	   influence	   a	   wide	   range	   of	   cellular	  
mechanisms,	  such	  as	  cell-­‐cycle	  control	  and	  apoptosis	  by	  binding	  to	  specific	  phosphorylated	  
sites	  on	  diverse	  proteins	  such	  as	  tumor	  suppressor	  proteins,	  and	  regulators	  of	  cell	  survival,	  
proliferation	  and	  growth	  (Mackintosh,	  2004).	  Since	  we	  found	  that	  AF4	  interacts	  with	  14-­‐3-­‐3	  θ	  
(Esposito	  et	  al,	  2011),	  we	  tested	  whether	  the	  MLL-­‐AF4	  chimaeras	  interact	  with	  14-­‐3-­‐3	  θ.	  The	  
flagged	  MLL-­‐AF4	  recombinant	  proteins	  were	  precipitated	   from	  whole	  cell	  extracts	  using	  an	  
antibody	  anti-­‐FLAG	  and	  the	  immunocomplexes	  analyzed	  by	  Western	  Blot,	  using	  an	  antibody	  
specific	   for	   14-­‐3-­‐3	   θ.	   The	   results	   show	   that	   both	   the	   usual	   and	   novel	   MLL-­‐AF4	   chimera	  
interact	  with	  14-­‐3-­‐3	  θ,	  suggesting	  that	   the	  MLL-­‐AF4	  proteins	  retains	  the	  binding	  domain	  of	  
AF4	  to	  this	  protein	  (fig.	  18).	  
Fig	  18.	  The	  14-­‐3-­‐3	  θ 	  protein	  interacts	  with	  MLL-­‐AF4	  chimaera.	  20	  µl	  of	  FLAG-­‐IP	  and	  50	  µl	  of	  
WCE	   of	   cells	   transfected	  with	   empty	   vector	   (mock)	   and	   p3XFLAG+usual/novelMLL-­‐AF4	   full	  
length	  were	  loaded	  on	  12%	  SDS-­‐PAGE	  and	  analyzed	  by	  western	  blot.	  The	  antibody	  directed	  
against	  the	  14-­‐3-­‐3	  θ	  detected	  a	  band	  at	  28	  kDa	  in	  all	  the	  input	  samples	  and	  in	  the	  IP	  of	  both	  
usual	  and	  novel	  MLL-­‐AF4.	  For	  this	  analysis	  the	  α-­‐14-­‐3-­‐3	  θ	  was	  used	  at	  a	  dilution	  of	  1:500.	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Since	  we	  found	  that	  14-­‐3-­‐3	  θ	  interacts	  with	  MLL-­‐AF4	  and	  as	  the	  14-­‐3-­‐3s	  are	  known	  to	  
bind	  and	  modulate	   the	   function	  of	   their	   target	  proteins,	  we	   investigated	   the	  effects	  of	   the	  
over-­‐expression	  of	  14-­‐3-­‐3	  θ	  on	  the	  aberrant	  transcriptional	  activity	  induced	  by	  MLL-­‐AF4.	  We	  
cotransfected	  the	  Hek293	  cells	  with	  both	  p3XFLAG-­‐usualMLL-­‐AF4	  and	  pCDNA3+14-­‐3-­‐3 θ,	  and	  
analyzed	   the	   expression	   levels	   of	   HoxA9.	   The	   Real	   Time-­‐PCR	   results	   showed	   that	  
overexpression	  of	  both	  MLL-­‐AF4	  and	  14-­‐3-­‐3	  θ	  rescued	  HoxA9	  expression	   in	  normal	   level	   in	  
the	  HEK293	  cells,	  compared	  to	  the	  cells	  transfected	  with	  p3XFLAG+usualMLL-­‐AF4.	  Therefore,	  
the	   data	   suggests	   that	   14-­‐3-­‐3	   not	   only	   interacts	   with	   MLL-­‐AF4,	   but	   also	   modulates	   its	  
transactivation	  activity	  (fig.	  19).	  
	  
Fig.	  19.	  The	  interaction	  between	  14-­‐
3-­‐3	  θ 	  and	  MLL-­‐AF4	  affects	  the	  MLL-­‐
AF4	  transcriptional	  activity.	  Hek293	  
cells	   were	   transfected	   with	   both	  
empty	   pcDNA3	   and	   p3XFLAG	  
vectors,	   p3XFLAG+usualMLL-­‐AF4	   full	  
length,	   pcDNA3+14-­‐3-­‐3	   θ,	  
respectively,	  and	  cotransfected	  with	  
both	   p3XFLAG+usualMLL-­‐AF4	   full	  
length	   and	   pcDNA3+14-­‐3-­‐3	   θ.	  
Expression	   level	   of	   HoxA9	   gene	   in	  
the	   transfected	   cells	   was	   evaluated	  
by	   Real-­‐Time	   PCR.	   In	   the	   single-­‐
transfected	  cells,	   the	   level	  of	  HoxA9	  
is	   increased	   (~2	   fold)	   compared	   to	  
the	  double	  mock	  control	  whereas	  in	  
the	   cotransfected	   cells,	   the	   level	   of	  
HoxA9	   transcript	   is	   rescued	  at	  basal	  
level.	   The	   fold	   increase	   has	   been	  
evaluated	   by	   the	   formula	   2-­‐∆∆Ct,	  
using	  β-­‐actin	  and	  β-­‐glucuronidase	  as	  
house-­‐keeping	  genes	  (mean	  ±	  SEM).	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3.8	  MLL-­‐AF4	  interacts	  with	  the	  Fibroblast	  Growth	  Factor	  Receptor	  2	  (FGFR2)	  
Surprisingly,	  the	  proteomics	  experiments	  revealed	  that	  the	  Fibroblast	  Growth	  Factor	  
Receptor	  2	  as	  an	   interactor	  of	   the	  native	  AF4	  protein	   (Esposito	  et	  al,	  2011).	  We	  found	  this	  
data	  particularly	  interesting,	  since	  both	  AF4	  and	  MLL-­‐AF4	  are	  nuclear	  proteins.	  Therefore,	  we	  
tested	   whether	   the	   MLL-­‐fusion	   proteins	   interact	   with	   this	   AF4	   interactor,	   by	  
immunoprecipitation	   and	   Western	   Blot	   experiments	   in	   Hek293	   cells	   transfected	   with	  
p3XFlag+MLL-­‐AF4.	   As	   shown	   in	   fig.	   20,	   a	   band	   has	   been	   found	   at	   the	   FGFR2	   expected	  
molecular	  weight	  (~120	  kDa),	  confirming	  that	  even	  both	  forms	  of	  MLL-­‐AF4,	  usual	  and	  novel,	  
interact	  with	  this	  receptor.	  
Fig	   20.	   MLL-­‐AF4	   oncoproteins	   interact	   with	   the	   Fibroblast	   Growth	   Factor	   Receptor	   2	  
(FGFR2).	   FLAG-­‐IP	   and	   WCE	   of	   cells	   transfected	   with	   empty	   vector	   (mock)	   and	  
p3XFLAG+usual/novelMLL-­‐AF4	   full	   length	   were	   loaded	   on	   8%	   SDS-­‐PAGE	   and	   analysed	   by	  
western	  blot	  with	  a	  FGFR2-­‐specific	  antibody.	  A	  band	  is	  detected	  at	  120	  kDa	  in	  all	   the	   input	  
samples	  and	  in	  the	  IP	  of	  both	  FLAG-­‐usualMLL-­‐AF4	  and	  FLAG-­‐novelMLL-­‐AF4.	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3.9	  FGFR2	  gene	  expression	  is	  higher	  in	  RS4;11	  than	  in	  697	  
	   	   The	  finding	  that	  the	  MLL-­‐AF4	  proteins	  interact	  with	  FGFR2	  lead	  us	  to	  hypothesize	  that	  
this	   receptor	   could	  have	  a	   role	   in	   the	  molecular	  pathogenesis	  of	   t(4;11)	  ALL.	   Therefore,	  we	  
investigated	  the	  expression	  of	  the	  FGFR2	  transcript	  in	  two	  different	  human	  hematopoietic	  cell	  
lines,	  i.e.	  the	  697,	  a	  human	  pre-­‐B	  leukemic	  cell	  line	  carrying	  the	  t(1;19)	  rearrangement	  (Planey	  
et	  al,	  2002),	  and	  the	  RS4;11,	  carrying	  the	  translocation	  of	  our	  interest.	  	  
	   	   As	   shown	   in	   fig.	  21,	  RT-­‐Real-­‐Time	  PCR	   results	   indicated	   that	   the	  FGFR2	   transcript	   is	  
more	  expressed	  in	  the	  cells	  expressing	  MLL-­‐AF4,	  compared	  to	  leukemic	  cells	  that	  do	  not	  have	  










Fig.	   21.	   FGFR2	   gene	   expression	   is	   higher	   in	   RS4;11	   than	   in	   697	   cells.	   Expression	   level	   of	  
FGFR2	   gene	  was	   evaluated	   by	   Real-­‐Time	   PCR	   in	   leukemic	   cell	   lines.	   The	   fold	   increase	   has	  
been	  calculated	  by	  the	  formula	  2-­‐∆∆Ct,	  using	  β-­‐actin	  as	  housekeeping	  gene	  (mean	  ±	  SEM).	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3.10	   A	   new	   cell	   model	   for	   MLL-­‐AF4:	   the	   human	   hematopoietic	   stem	   and	  
progenitor	  cells?	  
The	   CD34	   antigen	   is	   a	   highly	   glycosylated	   transmembrane	   protein	   member	   of	   the	  
sialomucinfamily	   of	   surface	   antigens.	   It	   is	   strongly	   expressed	   on	   human	   hematopoietic	  
stem/progenitor	   cells	   and	   its	   expression	   shows	   a	   progressive	   and	   rapid	   decline	   as	   HSCs	  
undergo	  differentiation	  (Caux	  et	  al,	  1989).	  Whereas	  the	  natural	   ligand	  for	  CD34	  has	  not	  yet	  
been	   identified	   in	   the	   hematopoietic	   microenvironment,	   it	   is	   expressed	   on	   murine	   high-­‐
endothelial	  venule	  cells	  in	  the	  lymph	  nodes	  and	  binds	  to	  the	  lymphocyte	  homing	  receptor	  L-­‐
selectin	   (Baumheter	   et	   al,	   1993).	   Hotfilder	   et	   al	   (2005)	   showed	   that	   the	  MLL-­‐AF4-­‐positive	  
cells	   in	   ALL	   patients	   are	   restricted	   to	   a	   CD34+CD19-­‐	   compartment,	   suggesting	   that	   the	  
chromosomal	   aberration	   takes	   place	   in	   a	   very	   undifferentiated	   cell	   that	   gives	   rise	   to	   the	  
leukemia.	  	  
We	   wanted	   to	   study	   the	   effects	   induced	   by	   the	   MLL-­‐AF4	   oncoprotein	   in	   human	  
hematopoietic	   stem	   cells	   (HSC).	   Methods	   used	   for	   HSCs	   isolation	   include	   fluorescence	  
activated	   cell	   sorting	   (FACS)	   and	   magnetic	   activated	   cell	   separation	   sorting	   (MACS),	   both	  
using	  either	  fluorescently	  or	  magnetically	  labeled	  specific	  antibodies	  (Sousa	  et	  al,	  2011).	  We	  
opted	  for	  CD34+	  immunomagnetic	  selection	  and	  collected	  from	  the	  Ceinge-­‐BioBank	  samples	  
of	  human	  cord	  blood	  that	  were	  not	  suitable	  for	  therapeutic	  purpose.	  We	  also	  evaluated	  the	  
purity	  and	  the	  yield	  of	  the	  procedure	  by	  flow	  cytometry	  (Fig.	  22).	  As	  expected,	  the	  average	  
yield	  of	  CD34+	  cells	  purified	  from	  fresh	  total	  cord	  blood-­‐derived	  cells	  by	  the	  immunomagnetic	  
procedure	   was	   ~0.3-­‐0.5%.	   Flow	   cytometry	   of	   the	   immuno-­‐separated,	   eluted	   fraction	   of	  
CD34+	  revealed	  a	  purity	  of	  83%.	  Only	  0.3%	  of	  cells	  in	  the	  flow-­‐through	  and	  in	  the	  wash	  were	  
CD34+.	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Fig.	   22.	   Purity	   analysis	   of	   immunoseparated	   cell	   fractions.	  A	   little	   aliquot	   of	   positive	   cell	  
fraction	  was	  analysed	  by	  flow	  citometry	  in	  order	  to	  estimate	  the	  purity	  degree	  of	  the	  MACS	  
enrichment.	  The	  83%	  of	  eluted	  	  cells	  were	  CD34+	  ,	  whereas	  only	  0.3%	  of	  cells	  in	  flow-­‐through	  
or	  wash	  fractions	  were	  CD34+	  (thanks	  to	  the	  kind	  collaboration	  with	  Dr	  Marica	  Gemei,	  Facility	  
of	  “Experimental	  and	  clinical	  citometry”,	  Ceinge	  Biotecnologie	  Avanzate	  s.c.a	  r.l.).	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We	  cultured	   the	  purified	  CD34+	   cells	   in	   IMDM	  with	  penicillin	   and	   streptomycin	   and	  
10%	  fetal	  bovine	  serum.	  24	  h	  after	  purification,	  cells	  were	  transfected	  with	  the	  usualMLL-­‐AF4	  
cDNA,	   cloned	   in	   p3xFLAG	   expression	   vector,	   and	   with	   the	   empty	   p3xFLAG	   vector	   (mock	  
control),	  respectively.	  Total	  RNA	  was	  extracted	  from	  MLL-­‐AF4-­‐transfected	  and	  mock	  cells	  for	  
real-­‐time	   RT-­‐PCR	   analysis,	   to	   first	   evaluate	   the	   expression	   of	   the	   MLL-­‐AF4	   chimaera	   and	  
verify	  the	  efficiency	  of	  cell	  transfection	  at	  mRNA	  level.	  As	  expected,	  the	  chimaera	  transcript	  
was	   detected	   only	   in	   the	   cells	   transfected	   with	   p3XFLAG+MLL-­‐AF4,	   thus	   confirming	   the	  
exogenous	   expression	  of	  MLL-­‐AF4	   in	   the	  HSPCs.	   Then,	   the	   real-­‐time	  RT-­‐PCR	  of	   FGFR2	  was	  
performed	  to	  verify	  the	  expression	  of	  this	  gene	  in	  the	  HSPCs	  enforced	  to	  express	  MLL-­‐AF4.	  	  
Our	  preliminary	  results	  evidenced	  that	  the	  exogenous	  expression	  of	  MLL-­‐AF4	  induced	  
increased	   FGFR2	   transcript	   levels	   in	   CD34+	   cells,	   indicating	   that	   the	   FGFR2	   gene	   and	   the	  
related	   pathway	   could	   be	   early	   target/marker	   of	   the	  MLL-­‐AF4	   oncogenic	   activity	   (Fig.	   23).	  
Further	  analysis	  needs	  to	  better	  evaluate	  the	  range	  of	  increased	  expression	  of	  FGFR2,	  due	  to	  




	  	  	  	  
Fig.	   23.	  MLL-­‐AF4	   up-­‐regulates	   the	   FGFR2	   transcript	   in	   hematopoietic	   progenitors.	   CD34+	  
cells	  were	  transfected	  with	  empty	  p3XFLAG	  vector	  (MOCK)	  and	  p3XFLAG+usualMLL-­‐AF4	  full	  
	   64	  
length,	  respectively.	  Expression	  level	  of	  FGFR2	  gene	  in	  the	  transfected	  cells	  was	  evaluated	  by	  
Real-­‐Time	  PCR.	  Preliminary	  results	  showed	  that	  in	  the	  MLL-­‐AF4-­‐transfected	  cells,	  the	  level	  of	  
FGFR2	   transcript	   is	   increased	   compared	   to	   the	   mock	   control.	   The	   fold	   increase	   has	   been	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Discussion	  	  
The	   t(4;11)	   reciprocal	   chromosomal	   translocation	   is	   associated	  with	   a	   B-­‐cells	   acute	  
lymphoblastic	   leukemia	   characterized	   by	   a	   very	   poor	   prognosis.	   Following	   the	   t(4;11)	  
chromosomal	  translocation,	  two	  chimeric	  protein	  take	  place	  in	  the	  leukemic	  clone:	  MLL-­‐AF4	  
on	  chromosome	  11	  and	  AF4-­‐MLL	  on	  chromosome	  4.	  This	  PhD	  project	  aimed	  to	  clarify	  some	  
aspects	   of	   the	   function	   of	   the	  MLL-­‐AF4	   fusion	   protein,	  which	   has	   the	   capability	   of	  MLL	   to	  
bind	  DNA	  and	   the	   strong	   transcriptional	   activation	  domain	  of	  AF4.	  Many	  data	   support	   the	  
hypothesis	  that	  this	  fusion	  protein	  sustains	  growth	  and	  proliferation	  of	  the	  malignant	  clone,	  
by	  mis-­‐regulating	  the	  expression	  of	  genes,	  such	  as	  HoxA9	  and	  Meis1,	  which	  are	   involved	   in	  
self-­‐renewal/differentiation	   balance	  of	   hematopoietic	   stem	   cells.	  Notably,	   down-­‐regulation	  
of	   these	   genes	   can	   somehow	   revert	   the	   leukemic	   phenotype.	   However,	   the	   aberrant	  
molecular	  mechanism	  induced	  by	  this	  oncoprotein	  remains	  poorly	  understood.	  	  
Functional	   proteomic	   experiments	   previously	   performed	   in	   our	   research	   group	  
identified	   many	   molecular	   interactors	   of	   the	   native	   AF4	   protein	   (Esposito	   et	   al,	   2011).	  
Based	  on	  the	  cell	  function,	  the	  identified	  molecular	  partners	  can	  be	  divided	  into	  different	  
groups.	  Most	  of	   them	  are	   involved	   in	   the	   regulation	  of	   the	  Pol	   II-­‐mediated	   transcription,	  
suggesting	   a	   direct	   role	   of	   AF4	   in	   this	   process.	   Thus,	   our	   first	   aim	   was	   to	   investigate	  
whether	   these	  proteins	  also	   interact	  with	  MLL-­‐AF4	   chimeric	  proteins.	   Therefore,	  we	   first	  
cloned	  the	  cDNAs	  encoding	  two	  different	  isoforms	  of	  MLL-­‐AF4:	  an	  “usual”	  form	  (usualMLL-­‐
AF4),	  which	  is	  the	  most	  common	  in	  t(4;11)	  ALL	  patients	  and	  a	  “novel”	  one	  (novelMLL-­‐AF4),	  
previously	  found	  in	  an	  infant	  ALL-­‐patient,	  that	   lacks	  part	  of	  the	  transactivation	  domain	  of	  
AF4.	   We	   obtained	   the	   cDNA	   that	   encodes	   the	   usualMLL-­‐AF4	   breakpoint,	   by	   using	   RNA	  
extracted	   from	   RS4;11	   cells,	   whereas	   the	   novelMLL-­‐AF4	   cDNA	   was	   created	   from	   the	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usualMLL-­‐AF4	  cDNA,	  by	  a	  series	  of	  amplification	  and	  ligation	  procedures.	  We	  cloned	  both	  
cDNAs	  in	  the	  eukaryotic	  p3XFlag	  expression	  vector	  and	  used	  these	  constructs	  to	  transiently	  
transfect	   HEK293	   cells.	   After	   confirming	   that	   our	   MLL-­‐AF4	   recombinant	   proteins	   were	  
properly	   expressed	   in	   our	   system,	  we	   evaluated	   the	   expression	   levels	   of	  HoxA9	   gene,	   a	  
well-­‐known	   target	   of	   the	   oncogenic	   activity	   of	   both	  wild-­‐type	  MLL	   and	   rearranged	   form	  
MLL-­‐AF4,	   by	   semiquantitative	   PCR.	   As	   expected,	   we	   found	   that	   in	   our	   expression	   cell	  
systems,	   the	   expression	   level	   of	   the	   HoxA9	   gene	   was	   increased.	   We	   also	   found	   by	  
immunofluorescence	  assay	  that	  both	  forms	  of	  MLL-­‐AF4	  localized	  in	  the	  nucleus,	  thanks	  to	  
the	  NLS	  of	  both	  MLL	  and	  AF4.	  Furthermore,	  we	  found	  that	  the	  chimaera’s	  portion	  lacking	  
the	  NLS	  of	  MLL	  still	  localize	  into	  the	  nucleus,	  thus	  validating	  the	  hypothesis	  that	  the	  NLS	  of	  
AF4	  alone	  is	  able	  to	  address	  the	  fusion	  proteins	  into	  the	  nucleus.	  
Starting	  from	  our	  previous	  proteomic	  data,	  we	  investigated	  the	  interaction	  of	  the	  
chimaera	  with	  the	  molecular	  partners	  of	  AF4,	  such	  as	  CRSP130,	  CRSP33,	  CdK9,	  14-­‐3-­‐3	  θ	  and	  
FGFR2,	  by	  co-­‐immunoprecipitation	  assay.	  	  
The	  CRSP130	  and	  CRSP33	  proteins,	  also	  known	  as	  Med7	  and	  Med23	  respectively,	  
belong	  to	  the	  so-­‐called	  Mediator	  Complex.	  This	  complex	  is	  able	  to	  bind	  directly	  to	  Pol	  II	  and	  
plays	  important	  roles	  at	  each	  stage	  of	  transcription,	  from	  the	  recruitment	  of	  Pol	  II	  to	  genes	  
in	  response	  to	  many	  signals	  to	  controlling	  Pol	  II	  activity	  during	  transcription	  initiation	  and	  
elongation	   (Conaway	   &	   Conaway,	   2011).	   We	   found	   that	   both	   chimaeras	   interact	   with	  
CRSP130	   subunit,	  but	  only	   the	  usual	   chimaera	  binds	   to	  CRSP33,	   suggesting	  not	  only	   that	  
the	  binding	  domain	  of	  AF4	  and	  MLL-­‐AF4	  to	  CRSP33	  localized	  in	  the	  portion	  of	  the	  AF4	  that	  
is	   lost	   in	   the	   novel	   isoform,	   but	   also	   that	   CRSP33	   is	   not	   crucial	   for	   the	   transforming	  
potential	  of	  the	  chimaeras.	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We	  also	   found	   that	  MLL-­‐AF4	   interacts	  with	   CdK9,	   the	   kinase	   activity	   of	   P-­‐TEFb.	  
Bitoun	  et	  al	  (2007)	  already	  showed	  that	  AF4	  enhances	  the	  transcription,	  by	  promoting	  the	  
kinase	  activity	  of	  CdK9	  on	  the	  C-­‐terminal	  domain	  of	  Pol	   II.	   It	   is	  possible	  that	  the	  MLL-­‐AF4	  
chimaeras	   bind	   to	   the	   promoters	   of	   MLL	   target	   genes	   and	   enhance	   their	   transcription,	  
according	  to	  the	  transcriptional	  activation	  mechanisms	  induced	  by	  AF4.	  The	  mis-­‐regulated	  
transcription	  of	  MLL	   target	  genes	   could	   contribute	   to	  explain	   the	   leukemic	  phenotype	  of	  
the	  hematopoietic	  cells	  with	  the	  t(4;11)	  rearrangement.	  Our	  findings	  about	  this	  interaction	  
seem	   to	   also	   fit	   the	   hypothesis	   formulated	   by	   Yokoyama	   et	   al	   (2010),	   i.e.	   that	   the	  MLL-­‐
fusion	   proteins	   are	   able	   to	   constitutively	   recruit	   at	  MLL	   loci	  all	   the	  members	   of	   the	  AEP	  
complex	   that	   are	   involved	   in	   the	   transcriptional	  machinery	  of	  RNA	  pol	   II.	   Then,	   aberrant	  
recruitment	  of	  the	  transcriptional	  complex	  at	  MLL	   loci	   leads	  to	  improper	  activation	  of	  the	  
MLL	  target	  genes,	  which	  alters	  differentiation	  of	  the	  hematopoietic	  cell	  affected	  by	  the	  MLL	  
gene	   molecular	   aberration	   (Fig.	   24).	   Furthermore,	   it	   is	   now	   clear	   that	   the	   MLL–AF4	  
chimaera,	   irrespective	   of	   the	   transactivation	   domain,	   is	   still	   able	   to	   recruit	   most	   of	   the	  
protein	   components	   that	   are	   necessary	   for	   the	   transcription	   of	   genes	   that	   enhance	   and	  
sustain	   cell	   transformation.	   Thus,	   these	   results	   corroborate	  what	  we	  previously	   reported	  
that	  even	  when	  MLL-­‐AF4	  chimaeras	  lack	  part	  of	  the	  AF4	  transactivation	  domain,	  they	  can	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Fig.	  24.	  Model	  of	  the	  protein	  network	  in	  which	  MLL-­‐AF4	  takes	  part	  in	  the	  nucleus.	  Thanks	  
to	   the	   Nuclear	   Localization	   Signals	   of	   both	  MLL	   and	   AF4	   proteins,	   the	   chimaera	  MLL-­‐AF4	  
migrates	   into	   the	   nucleus.	   Here,	   the	   oncoprotein	   is	   able	   to	   recruit	   many	   components	  
necessary	   for	   the	  Pol	   II-­‐mediated	  gene	  transcription	  and	  activates	  the	  expression	  of	  HoxA9	  
and	   other	   target	   genes	   that	   enhance	   and	   sustain	   the	   oncogenic	   transformation	   in	   the	  
hematopoietic	  cell.	  	  
	  
	   Since	  the	  functional	  proteomics	  assay	  interestingly	  revealed	  the	  interaction	  between	  
AF4	  and	  14-­‐3-­‐3	  θ,	  the	  latter	  involved	  in	  many	  cellular	  functions,	  including	  signal	  transduction,	  
cell-­‐cycle	  control	  and	  apoptosis,	  we	  investigate	  the	  possible	  interaction	  between	  this	  protein	  
and	   chimaera.	   The	   immunoprecipitation	   assays	   confirmed	   that	  both	   the	  MLL-­‐AF4	   isoforms	  
bind	  to	  14-­‐3-­‐3	  θ.	  Therefore,	  since	  the	  14-­‐3-­‐3s	  are	  known	  to	  modulate	  the	  function	  of	  their	  
target	  proteins,	  we	  analyzed	  the	  effects	  of	  the	  co-­‐expression	  of	  14-­‐3-­‐3	  θ	  and	  MLL-­‐AF4	  on	  the	  
expression	   of	   HoxA9,	   the	   main	   MLL-­‐AF4	   target	   gene.	   We	   observed	   a	   lower	   HOXA9	   gene	  
expression	   in	   the	   co-­‐transfected	   cells	   compared	   to	   the	   cells	   transfected	  with	   the	   chimera	  
cDNA	  alone.	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   According	   to	   the	  evidence	   that	  14-­‐3-­‐3s	  bind	  many	  nuclear	  phosphorylated	  proteins	  
and	   control	   their	   rate	   of	   nuclear	   import/export,	   thereby	  modulating	   various	   transcriptional	  
processes	   (Mackintosh,	   2004).	   Because	  MLL-­‐AF4	  preserves	   the	   binding	   site	   to	   14-­‐3-­‐3	  θ,	  we	  
may	   suppose	   that	   14-­‐3-­‐3	   θ	   could	   regulate	   the	   nuclear	   transfer	   of	   the	   chimaera	   and	  
consequently	  its	  activity	  on	  the	  target	  gene	  expression	  (Fig.	  25).	  Further	  experiments	  aimed	  to	  
investigate	   the	   significance	   of	   the	   interaction	   between	   14-­‐3-­‐3	  θ	   and	  MLL-­‐AF4	   are	   currently	  
ongoing	  in	  our	  laboratories.	  
	  
	  
Fig.	  25.	  Model	  of	  the	  likely	  modulation	  on	  HoxA9	  expression	  by	  14-­‐3-­‐3	  θ .	  A	  phosphorilation	  
residue	  of	  MLL-­‐AF4	  in	  the	  AF4	  portion,	  could	  work	  as	  a	  docking	  site	  for	  the	  recruitment	  of	  14-­‐
3-­‐3	  θ	  in	  the	  cytosol.	  This	  binding	  could	  sequester	  the	  chimaera	  in	  the	  cytosol	  and	  prevent	  its	  
migration	  into	  the	  nucleus,	  thus	  inhibiting	  the	  activation	  of	  HoxA9	  gene	  expression.	  
	  
	   	  
	   	   Surprisingly,	  we	  have	  also	  found	  that	  MLL-­‐AF4,	  as	  well	  as	  AF4,	  interacts	  with	  FGFR2.	  
Unpublished	  data	  from	  our	  group	  found	  demonstrated	  that	  this	  binding	  occurs	  in	  the	  nucleus.	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Moreover,	   in	  this	  study,	  we	  found	  a	  higher	  expression	  of	  the	  FGFR2	  transcript	   in	  the	  RS4;11	  
hematopoietic	   cells	   than	   in	  697,	  a	  non-­‐t(4;11)	   leukemia-­‐cell	   line,	   thus	   indicating	   that	  FGFR2	  
could	  be	  overexpressed	  in	  the	  hematopoietic	  cells	  carrying	  t(4;11).	  	  
	   	   MLL-­‐AF4	   has	   been	   previously	   associated	   to	   a	   membrane	   receptor,	   the	   Insulin-­‐like	  
Growth	   Factor-­‐1	   receptor	   (IGF1R),	   which	   is	   down-­‐regulated	   as	   a	   result	   of	   the	   HoxA9	  
knockdown	   in	   RS4;11	   cells.	   In	   contrast,	   HoxA9	   overexpression	   induces	   IGF1R	   expression,	  
suggesting	   that	   the	   receptor-­‐associated	   pathway	   could	   yield	   new	   potential	   targets	   for	   the	  
treatment	  of	  leukemias	  or	  other	  cancers	  that	  show	  the	  overexpression	  of	  Hox	  genes	  (Whelan	  
JT	  et	  al,	  2008).	  	  
Our	   findings	   strongly	   indicate	   that	   FGFR2	   could	   be	   implicated	   in	   the	   molecular	  
pathway	   triggered	   by	   the	   MLL-­‐AF4	   oncoprotein.	   However,	   we	   do	   not	   know	   yet	   how	   the	  
transduction	  pathway	  triggered	  by	  FGFR2	  (Fig.	  26)	  could	  fit	  in	  the	  molecular	  pathogenesis	  of	  
the	  t(4;11)	  ALL.	  Our	  perspective	  will	  be	  to	  clarify	  the	  role	  of	  this	  transmembrane	  receptor	  in	  
the	  pathway	  induced	  by	  MLL-­‐AF4,	  thereby	  opening	  the	  possibility	  to	  interfere	  this	  pathway,	  
by	   designing	   specific	   inhibitors	   that	   could	   be	   used	   in	   targeted	   therapy.	   Nowadays,	   other	  
types	  of	  ALL	  are	  successfully	  treated	  with	  drugs	  that	  specifically	  target	  the	  molecules	  directly	  
involved	   in	   the	   pathomechanism	   induced	   by	   the	   aberrant	   oncoprotein.	   As	   well	   as	   the	  
Philadelphia	   Chromosome-­‐Positive	   ALL	   is	   currently	   treated	   with	   the	   last	   generation	   TKIs	  
(Tyrosine-­‐Kinase	   Inhibitor)	   in	   successful	   combination	   with	   established	   antileukemic	   agents	  
(Lee	   et	   al,	   2011),	   targeting	   the	   FGFR2	   pathway	   at	   the	   different	   steps	   could	   be	   used	   as	  
coadiuvant	  to	  the	  standard	  treatment	  of	  the	  t(4;11)-­‐positive	  ALL,	  avoiding	  relevant	  therapy-­‐
related	  issues	  such	  as	  cytotoxicity	  and	  chemioresistance.	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Fig.	  26.	  The	  signalling	  pathway	  of	   the	  tyrosine-­‐kinase	  receptor	  FGFR2.	  After	   the	  substrate	  
(FGF)	  binding,	  the	  receptor	  dimerizes	  thereby	  leading	  to	  autophosphorylation	  of	  intracellular	  
tyrosine	   residues	   that	   serve	   to	   recruit	   SH2	   domain-­‐containing	   proteins	   and	   initiate	  
downstream	   signalling.	   The	   recruitment	   of	   the	   Ras	   activator	   SOS	   through	   the	   Grb2/FRS2	  
complex	   activates	   the	   extracellular	   signal-­‐regulated	   protein	   kinase	   (ERK)	   pathway.	  
Phosphorylated	   forms	  of	  ERKs	   translocate	   to	   the	  nucleus	  where	   they	  activate	   transcription	  
factors	   involved	   in	   cell	   cycle	   control.	   The	   FGFR2	   transduction	   also	   activates	   the	  
phospholipase	   Cγ/protein	   kinase	   C	   and	   the	   phosphoinositide-­‐3-­‐kinase	   (PI3K)/Akt-­‐signaling	  
cascades	  (Melnic	  et	  al,	  2009).	  
	  
	  
We	   also	   started	   to	   study	   the	   aberrant	   pathway	   induced	   by	  MLL-­‐AF4	   in	   the	   human	  
hematopoietic	  stem	  and	  progenitor	  cells.	  Therefore	  we	  enriched	  the	  CD34+	  cell	  from	  human	  
umbilical	  cord	  blood-­‐derived	  cells.	  In	  the	  meantime	  we	  were	  looking	  for	  the	  best	  conditions	  
for	   studying	   the	  effects	  of	   the	  ectopic	  expression	  of	  MLL-­‐AF4	   in	   the	  human	  hematopoietic	  
stem	  and	  progenitor	  cells,	  Montes	  et	  al	  (2011)	  published	  a	  paper,	  showing	  that	  the	  enforced	  
expression	   of	   MLL-­‐AF4	   in	   human	   cord	   blood-­‐derived	   cells	   enhances	   the	   hematopoietic	  
repopulating	  cell	   function	  and	  clonogenic	  potential.	  However,	   these	  events	  seem	  to	  be	  not	  
sufficient	   for	   initiating	   leukemogenesis	   in	   vivo.	   This	   inability	   to	   develop	   a	   MLL-­‐AF4+	   ALL	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disease	  model	  based	  on	  human	  cord-­‐blood-­‐CD34+	  progenitors	  suggests	  either	  that	  secondary	  
mutations	  or	  the	  AF4-­‐MLL	  reciprocal	  product	  might	  be	  required	  to	  develop	  ALL	  or	  that	  the	  
CD34+	  HSPCs	  from	  umbilical	  cord	  blood	  are	  not	  an	  appropriate	  model	  to	  study	  this	  pathway.	  
It	   has	   to	  be	   considered	   that	  earlier	  hematopoietic	  progenitors	   (fetal	  CD34+	   cells	   or	  human	  
ESC-­‐derived	   CD34+	   cells)	   could	   represent	   a	   more	   suitable	   system	   to	   study	   the	   MLL-­‐AF4	  
oncogenic	  pathway	  and	  could	  be	  used	  as	  a	  model	  to	  analyze	  aberrant	  pathway	   induced	  by	  
the	  MLL-­‐AF4	  oncoprotein	  which	  could	  lead	  the	  discovery	  of	  novel,	  early	  molecular	  markers	  of	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